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Introduction
                                                   
 INTRODUCTION
Diabetes mellitus
The  term  Diabetes  is  a  multifarious  group  of  disorders  characterized  by
hyperglycemia that has reached epidemic proportions in the current century. Infection is
a leading cause of morbidity and mortality among the diabetic population. Diabetes is
involved with vascular and renal damage characterized by hypertension, dyslipidemia,
micro-albuminuria,  macro-albuminuria  and  glomerular  mesangial  rise5.
 Diabetes
mellitus may present with characteristic symptoms such  as polyphagia, polydypsia,
polyuria, blurring of vision, and weight loss. In its severe forms, ketoacidosis or a
non-ketonic hyperosmolar state may develop and lead to stupor,  coma and  in  the
absence of effective treatment to death6. 
Epidemiology
Type-1 diabetes mellitus account for  10 % of all cases of diabetes mellitus  and
results  from  an  autoimmune  destruction  of  the  pancreatic  β-cells. The prevalence
of  β-cell  autoimmunity  appears  proportional  to  the  incidence  of  Type-1 diabetes
mellitus. In population groups. In countries like Sweden, Sardinia and Finland have the
highest number  prevalence of islet cell antibody (3%-4.5%) and are associated with
the high incident of Type-1 diabetes mellitus, 22-35 per 100,000. 
Type-2 diabetes mellitus is heterogeneous disorder of glucose metabolism. Type-2
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diabetes mellitus accounts for much as 90% of all cases of diabetes mellitus and
usually results from defects in insulin sensitivity and a relative defect in insulin
secretion7. 
 
According  to  WHO  (World  health  organization)  predictions,  the  prevalence  of
diabetes is to increase by 35%. Currently, there are over 150 million diabetic patients
worldwide and  this  is  likely to  increase  to  300 million or  more by the year  2025.
Statistical estimations about India reveals that the cases of diabetics will increase from
15 million in 1995 to 57 million in the year 2025, the highest number of diabetic cases
in the world 8.
Fig.no.1
Table 1  :  Top  ten  countries  for  estimated  number of  adults  with  diabetes
mellitus in million
Sr.No. Country 1995 Country 2025
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1. India 19.4 India 57.2
2. China 16.0 China 37.6
3. U.S. 13.9 U.S. 21.9
4. Russian 8.9 Pakistan 14.5
5. Japan 6.3 Indonesia 12.4
6. Brazil 4.9 Russian 12.2
7. Indonesia 4.5 Mexico 11.7
8. Pakistan 4.3 Brazil 11.6
9. Mexico 3.8 Egypt
10. Ukraine 3.6 Japan 8.5
All other countries 49.7 103.6
Total 135.3 300.0
THE PANCREAS:
Pancreas is a flattened organ lying to the posterior wall of the upper abdomen. The
bulk of the gland consists of acinar cells that synthesize and secrete digestive enzymes
that  enter  the duodenum  via  the  pancreatic  duct  system,  involving  the  exocrine
function. Scattered more or less randomly through the pancreas and accounting for only
1-2%  of its  weight are many  microscopic nests of cells,  the ‘islets of langerhans’,
which  constitute the endocrine pancreas, secreting several critically essential hormones
directly into the blood stream9. 
Pancreas of human has 1-2 million islets of langerhans, each having a diameter of
0.3mm and organized in circular round small capillaries in to which its cells secrete
hormones10. The pancreatic islet includes four types of hormone secretions,
1.   Alpha (α)  or A cells constitute about 20% of pancreatic islet cells and secrete
glucagon
2.   Beta (β) or B cells constitute about 70% of pancreatic islet cells and secrete
insulin
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3.   Delta (δ)  cells  or  D cells  constitutes about  5% of  pancreatic islet  cells  and
secrete somatostain .
4.   F cells constitute the remainder of pancreatic islet cells and secrete pancreatic
Polypeptide11. Regulates release of pancreatic digestive enzyme. Two minor cell types,
called D1 cells and enterochromaffin cells are seen in islets.
 D1  cells elaborate  vasoactive  intestinal  polypeptide,  a  hormone  that  results
glycogenolysis and hyperglycemia12.
Diagnostic Criteria13
The clinical diagnosis of diabetes is of prompted by symptoms such as
increased thirst and urine volume, recurrent infections and weight loss in severe cases,
drowsiness and coma; high levels of glycosuria are usually present.
Table:2. Values  for  diagnostic  of  diabetes  mellitus  and  other  categories  of
hyperglycemia according to the WHO
Glucose concentration (mmol / L)
Whole blood Plasma
Venous Capillary Venous Capillary
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Di  a    betes  mellitus
Fasting or load ≥ 6.1 ≥ 6.1 ≥ 7.0 ≥ 7.0
2-h post glucose of both ≥ 10.0 ≥ 11.1 ≥ 11.1 ≥ 12.2
Impaired glu  c  ose   tole  r  a    nce  (IGT)
Fasting (if measured) and < 6.1 and < 6.1 and < 7.0 and < 7.0 and
The revised diagnostic criteria for diabetes (according to the American diabetes
Association ADA) are as follows.14
Random plasma glucose : 11.1  mmoL  /  l  (200  mg/dL)  Fasting
plasma              glucose :  7.0 mmoL / l (126 mg/dL)
Classification of Diabetes mellitu
s
15
            The classification reveals both clinical stages and etiological types of
diabetes  mellitus and  categories  of hyperglycemia. Diabetes progresses with
several clinical stages.  Individual subjects progress from stage to stage. Diabetes
mellitus can be categorized by stage according to the clinical characteristics, even in
the absence of in concerning etiology information. The classification by a etiological
type results from understanding the causes of diabetes mellitus.
(1) Type-1 diabetes
Islet beta-cell destruction, usually leading to absolute insulin deficiency
A.  Autoimmune B. Idiopathic
(2) Type-2 diabetes
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Heterogenous-may range from predominantly insulin resistance with relative
insulin deficiency to a predominantly secretary defect with or without insulin
resistance.
(3) Genetic defects of beta-cell function 
                     1.  Chromosome 20, HNF4α  
                                                           (Formerly MODY 1)
                      2.  Chromosome 7, glucokinase
                                                        (Formerly MODY 2)
(5) Diseases of the exocrine pancreas
1.  Fibrocalculous pancreatopathy
2.  Pancreatitis
3.  Trauma / pancreatectomy
4.  Neoplasia
5.  Cystic fibrosis
6.  Haemochromatosis
(6) Endocrinopathies
1.  Cushing's syndrome
2.  Acromegaly
3.  Phaeochromocytoma   
4.  Glucagonoma
5.  Hyperthyroidism
6.  Somatostatinoma
(7)  Drug- or chemical-induced
1.  Nicotinic acid
2.  Glucocorticoids
3.  Thyroid hormone
4.  Alpha-adrenergic agonists
      5.  Beta-adrenergic agonists
6.  Thiazides
7.  Dilantin
8.  Pentamidine
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9.  Vacor
10. Interferon-alpha therapy
(8) Infections
1.  Congenital rubella
2.   Cytomegalovirus
(9) Uncommon forms of immune-mediated diabetes
1.  Insulin autoimmune syndrome
(Antibodies to insulin)
  (10) Other genetic syndromes
1.  Down's syndrome
2.  Friedreich's ataxia
3.  Huntington's chorea
4.  Klinefelter's syndrome
5.  Lawrence-Moon-Biedel syndrome
6.  Myotonic dystrophy
7.  Porphyria
8.  Prader-Willi syndrome
9.  Turner's syndrome
10. Wolfram's syndrome
Type-1 diabetes mellitus
Type
 1 indicates the processes of beta–cell destruction that may ultimately lead
to  diabetes mellitus in which “insulin is required for survival” to prevent the
development of ketoacidosis, coma and death.16
Type-2 diabetes mellitus
Type-2 diabetes mellitus is a heterogeneous disorder characterized by some
degree of insulin resistance with variable insulin secretion. Insulin secretion is said to
be relatively deficient because many patients may have normal to elevated levels of
insulin. However their blood sugars remain elevated because of tissue resistance to
the action of the insulin that is not usually life threatening.17
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Genetics
Genetic factors account for about one-third of the susceptibility to Type-2
diabetes.  Over  20 different regions of the human genome show some linkage with
Type-1  diabetes,  but  more  interest  has  been  focused  on  the  Human  Leucocyte
Antigen (HLA) region within the major histocompatibility complex on the short arm
of chromosome 6. This locus is designated IDDM-1. The HLA haplotype DR3 and /
or DR4 are associated with increased suspectibility to Type-1 diabetes in Caucasians.
Genetic factor are more important in the etiology of Type-2 than Type-1 
diabetes as shown by studies in monozygotic twins where concordance rates for Type-2
diabetes approach 100%.
The
 majority of cases of Type-2 diabetes are multifactorial in nature, with
interaction of environmental and genetic factor. The nature of the genetic contribution
is largely unknown but it is evident that several genes are involved.18
Maturity onset-diabetes of young
MODY is associated with autosomal dominant inheritance and is
characterized by age of onset in at least one family member prior to age 25 years, and
absence of ketosis. At least four genetically different types of MODY have been
described. Some patients will ultimately require insulin to control glycemia.19
Other genetic defects in insulin action21
A partial list of the genetic defects in insulin action include a number of well
described conditions, including Type-A insulin resistance, leprechaunism, Rabson –
menden hall syndrome and the lipoatrophic syndromes.
Pancreatic Disease20
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Acute Pancreatitis: Transient hyperglycemia may require  insulin  therapy.
Permanent  diabetes  is  unlikely  to  follow  a  single  episode  of  pancreatitis  unless
massive pancreatic destruction occurs.
Chronic Pancreatitis:   Chronic pancreatitis is frequently complicated by glucose
intolerance  or  diabetes  and  at  least  in  western  countries,  is  often  attributable  to
alcoholism. Pancreatic calcification may be evident on radiographs or computerized
tomography.
Endocrinopathies20
Several  hormones (e.g.  growth    hormone,  cortisol,    glucagon,    epinephrine)
antagonize   insulin action. Diseases associated with excess secretion of these
hormones can cause diabetes (e.g.Acromegaly, Cushing’s syndrome, Glucagonoma and
Phaeochromocytoma).   These  forms of  hyperglycemia  typically resolve  when   the
hormone excess is removed. Somatostatinoma, and aldosteronoma–induced
hypokalemia, can  cause  diabetes,  at  least  in  part  by  inhibiting  insulin  secretion.
Hyperglycemia generally resolves following successful removal of the tumor.
Gestational diabetes mellitus complicates roughly 4% of all pregnancies. Clinical
recognition is important to reduce associated morbidity and mortality. Most women
will  return to a normoglycemia   postpartum but 30%-50% will develop diabetes
mellitus or glucose intolerance later in life.
Pathogenesis of Type-1 Diabetes mellitus21
Three interlocking mechanisms are responsible for the islet cell destruction:
1. Genetic Susceptibility
2. Auto-Immunity
3. Environmental
Genetic Predisposition
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           HLA – linked genes and other genetic loci
Environment Insult
Immune  response  against  normal β
cells AND / OR Immune  response
against altered β-cells
 Viral1infectionMolecular
mimicry AND / OR Damage to β-
cells
               Auto-Immune Attack
                     β-cells destruction
              Type 1 diabetes
         Fig: Pathogenesis of Type-1 diabetes mellitus
1. Genetic Susceptibility
               At least one of the susceptibility gene for Type-1 diabetes resides in the
region that encodes the class II antigens of the Major Histo compatibility Complex
(MHC) on chromosome GP21 (HLA-D).  The HLA-D region contains three classes
of genes (DP, DQ and DR). The class II molecules are   highly   polymorphic and
each has numerous alleles.
               About 95% of white patient with Type-1 diabetes have either HLA-DR3 or
HLA- DR4 alleles or both where as in the general population the prevalence of these
antigens is  only 45%. It is thought that genetic variations in the HLA class II
molecules may alter recognition by the T-cell receptor, or may modify the presentation
of the antigen because of variations in the antigen-binding cleft, thus, class II HLA
gene may effect the degree of immune responsiveness to a pancreatic β-cell auto
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antigen or a β-cell auto  antigen may be  presented  in  a  manner  that  promotes  an
abnormal immunologic reaction.
2. Auto-Immunity
Clinical onset of Type-1 diabetes is abrupt; this disease in fact results from a
chronic   auto-immune attack of β-cells that usually exists for many years before
the  disease  becomes  evident.22 A lymphocyte with rich inflammatory infiltrate
(insulitis) is observed in the islets  of patients in early diabetes. The infilteration
consists mostly of CD8 T- lymphocytes, plus variable numbers of CY4T cells and
macrophages. CD4T cell from animals with  auto immune diabetes can  transfer
diabetes to normal animals, thus establishing the primary of T-cell auto-immunity in
Type-1 diabetes.
The insulitis is associated with increase expression of class I MHC molecules and
aberrant expression of class II MHC molecules on the β-cells. This abberrant
expression is mediated in part by locally produced cytokines [eg. Interferon-gamma
(IFN-γ) derived  from activated T-cells]. Genetic dysregulation of a cytokine that
induce IFN-γ production promotes the development of diabetes in a mouse model.23
About 70%-80% of patients with Type-1 diabetes have islet cell auto antibodies
against intracellular islet cell antigens, such as GlutamicAcid Decarboxylose (GAD)
“islet auto antigen 2” (1a-2a tyrosine phosphatase), insulin and gangliosides.
3. Environmental Factors
Viruses
Epidemiologic studies suggest the action of viruses. A viral infection has long
been noted in   the diagnosis of new cases, and has the association between
coxsackie viruses of group B and   pancreatic diseases including diabetes. Other
implicated viral  infections  include  mumps,  measles,  cytomegalovirus,  rubella  and
infectious mononucleosis.
It has been postulated that one of that viruses causes mild β-cells injury, which is
followed by an auto-immune reaction against previously sequestered antigens in
virally altered β-cells in persons with HLA-linked susceptibility. Another is that an
immune response develops against a viral protein that shares amino acid sequences
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with a β-cell protein (molecular mimicry).
Others
Antigenic exposure may also come from other sources. Children who ingest cow’s 
milk products early in life (before age of 4 months) have a 1.5 fold increase risk for 
Type-1 diabetes relative to those who do not, raising the spectrum of a cross-reacting 
antigen in cow’s milk.
Normal insulin production and effects24
Insulin is a protein composed of 51 amino acids in two chains (A and B chains),
connected by two disulfide bonds. Insulin is synthesized and stored in the β-cells of
the islets of Langerhans, which are located in the pancreas. The pancreas produces a
parent  protein called pre  pro-insulin. Pre  pro-insulin is claved to form a smaller
protein, proinsulin. Proinsulin is claved to form equimolar amounts of C-peptide and
insulin. The normal  pancreas contains approximately 200U insulin, and a basal
amount of insulin is secreted continuously at a rate of approximately 0.5 to 1.0 U/h.
Additional insulin is also released in  response to blood glucose levels of 100 mg/dL
or more. The average daily insulin secretory rate in the adult is 25 to 50 U/day.
Insulin is cleared metabolically by the liver, peripheral tissues, and kidneys.   Insulin
follows first-order elimination kinetics, and the serum half-life is approximately 4 to 5
minutes.
The important metabolic sites that are sensitive to insulin include the liver, where
glycogen   is   synthesized,   stored   and   broken   down;   skeletal   muscle,   where
glucose  oxidation produces energy; and adipose tissue, where glucose can be
converted to fatty  acids, glyceryl phosphate and triglycerides. Insulin affects
carbohydrate, protein and lipid metabolism.
Carbohydrate metabolism
In patients without diabetes, insulin acts in concert with glucagon, somatostain,
growth    hormone,  corticosteroids,  epinephrine  a n d  p a r a s y m p a t h e t i c
i n n e r v a t i o n  t o  maintain blood glucose between 40 and 160  mg/dL at all times.
Three cell Types, α-cells, β-cells and δ-cells, have been identified in the islets of
Langerhans of the pancreas. The α-cells produce glucagons, a hormone that acts to
increase blood glucose levels. The β- cells produce, store and release insulin. The δ-
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cells produce somatostain, which inhibits  both insulin and glucagon secretion and
suppresses growth hormone. The suppression of glucagon by somatostain decreases
blood glucose levels and its effect persists for roughly 60 to 120 minutes.
Euglycemia is maintained by the three previously identified hormones working in
concert. Ingestion of a carbohydrate load results in a prompt increase in the amount
of  insulin release and a concomitant decrease in plasma glucagon. Glucagon is
released in  response to low blood glucose levels and protein ingestion. Glucagon
release stimulates  insulin secretion; insulin in turn inhibits glucagon release. The
presence of insulin favors the uptake and use of glucose by insulin-sensitive sites.
In skeletal muscle, glucose uptake and subsequent energy production increase. In the
liver, glucose uptake and the formation of glycogen increase in the presence of
insulin. A minimum blood glucose level of 40 mg/dL is needed to provide adequate
fuel for the brain, which can use only glucose as fuel and does not depend on the
presence of insulin for its use. Glucose spills into the urine, resulting in energy and
water loss, when blood glucose levels exceed the renal threshold (180 mg/dL).
Protein metabolism
The  presence  of  insulin  favors  the  production  of  structural  proteins  from
constituent   amino acids. When glucose is present intra  cellularly in sufficient
quantities for   needed   energy   production,   most   structural   proteins   retain   their
integrity.   In the absence of insulin, structural protein production is not favored, and
intracellular glucose levels are insufficient to match energy demands. In attempt to
produce energy, skeletal muscle converts its structural proteins to constituent amino
acids.  The liberated amino acids   are   transported   to   the   liver,   where   they   are
converted   to   glucose   via gluconeogenesis. In patients with diabetes, glucose enters
the blood but is not taken up by tissues because of a true or relative lack of insulin.
Thus, hyperglycemia is escalated, and structural proteins are wasted.
Fat metabolism
The presence of insulin favors the production of triglycerides from free fatty acids
(FFAs).  When insulin deficiency causes an energy deficit, FFAs are oxidized to β-
Hydroxybutyric acid, acetoacetic acid and acetone. β -Hydroxybutyric acid can be used
as an energy source, but in the absence of insulin the production of the keto acids
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eventually is greater than their metabolism and excretion.
 If insulin is not given to the patient,  metabolic ketoacidosis ensues. The keto
acids cause the blood pH to decline and diuresis secondary to the elimination of
ketones and glucose causes dehydration. The body’s neutralizing factors eventually
are depleted, and the patient continues to deteriorate to the point of coma and possibly
death. Fig: shows the clinical manifestations of the untreated patient with  Type-1
diabetes who is insulinopenic (complete lacks insulin).
URINE BLOOD MUSCLE AND
(Inability of glucose to get
ADIPOSE 
CELLS
Into cell due to lack of insulin) Insulin blocks
GLUCONEOGENESIS (Lipase)
(Amino acids changed to
carbohydrates and liver Stored Fats Free Fatty Acids 
glycogen converted to glucose)
Glycos
uria
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Pathogenesis of Type-2 Diabetes mellitus25
The two metabolic defects that characterize Type-2 diabetes are:
1.  A derangement in β-cell secretion of insulin
2.  A decrease response of peripheral tissue to respond to insulin
(Insulin resistance)
1. Deranged β-cell secretion of insulin
A  modest  hyper  insulinimia  may  be  observed,  attributed  to  β-cell  hyper
responsiveness to physiologic elevations in blood glucose, with the development of
overt disease. The pattern of insulin secretion exhibits a subtle change. Early in the
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course of Type-2 diabetes,  insulin secretion appears to be normal and plasma
insulin levels are not reduced.
However, the normal pulsatile oscillating pattern of insulin secretion is lost and
the rapid first phase of insulin secretion triggered by glucose is obtunded.
Collectively, these and other observations suggest derangements in β-cell response to
hyperglycemia early in Type-2 diabetes, rather than deficiencies in insulin synthesis
per se. Later in the cause of Type-2 diabetes a mild to moderate deficiency of insulin
develops which is less severe than that of Type-1.
2. Insulin Resistance
Insulin resistance  is  a  common  pathologic  state  in  which  target  cells  fail  to
respond to ordinary levels of circulating insulin. It is frequently associated with a
number  of diseases, including   chronic infection, human obesity and Type-2
diabetes.26   At the  molecular level, impaired insulin   signaling results from
mutations or post translation modification of the insulin receptor itself or any of its
down-stream effector molecules.  Insulin resistance could be accounted for by a
defect in insulin binding to its receptor, there may be a decrease in the number of
insulin receptor and more important, post receptor signaling by insulin is impaired.
The binding of insulin to its receptor leads to translocation of glucose transporter
(GLUT’s) to the cell membrane, which in turn facilitates cellular uptake of glucose. It
is  suspected that reduced  synthesis and translocation of glucose transporter
(GLUT’s) in muscle and fat cells underlies the insulin resistance noted in obesity as
well as in Type-2 diabetes.
Obesity
Approximately 80% of Type-2 diabetic are obese with abdominal obesity having a
greater impact. Intra-abdominal fat catabolism delivers free fatty acids to the liver,
yet is relatively resistant to   the  modulating effects of insulin. Although abdominal
obesity and insulin resistance could be coincidental expressions of a third unknown
factor, the possibility that they are casually related must be considered.
Amylin
Amylin, a 37 amino acid peptide is normally produced by the β-cells co-packaged
with insulin and co secreted with insulin in response to food ingestion. In patients
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with Type-2 diabetes, Amylin tends to accumulate in the sinusoidal space outside the β-
cells,  in close contact with their cell membrane, eventually acquiring the tinctorial
characteristics of amyloidal.27 It is unknown whether Amylin deposition contributes
to the disturbance in glucose sensing by the β-cells, noted early in the course of Type-2
diabetes or is instead a result of disordered β-cell function.
Patients with Type-2 diabetes may have an elevated, normal or low level of
circulating insulin, depending on the chronicity of their disease, and have a relative
lack of effective insulin. In patients with Type-2 disease, insulin and glucose levels
usually are  adequate to prevent ketoacidosis development. However, glucose can
accumulate in the blood and can reach extremely high levels (more than 400 mg/dL),
resulting in non ketotic hyper osmolar syndrome (NKHS). 25
Risk factors for complication of Diabetes mellitus28
Fixed risk factor:
Duration of diabetes: A linear relationship with the duration of the diabetes.
Age: The older the individual with, the greater the chance for complication, 
including cardiovascular and neuropathic complications.
Genetics: A relationship exists but is not really predictive.
Race: African-American individuals are more at risk for macro  vascular and
neuropathic changes but have a lower prevalence rate of myocardial infarction than
Caucasians,  Mexicans-american individual  seem to hence an increased risk for
peripheral vascular disease.
Gender:  Premenopausal women without diabetes are less at risk than males 
without diabetes for cardiovascular events and complications, but not females without 
diabetes. 
Height: Taller individuals seem to experience more neuropathy than other 
patients with
diabetes.
Modifiable risk factors:
Hyperglycemia:
Treating  hyperglycemia  lowers  the  incidence  of  many complications,  including
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neuropathy, retinopathy. Suggestive evidence is present to support the protective effect
for cardio vascular disease, though it is not conclusive. 
Hypertension: Plays a role in cardiovascular complication and neuropathy,
nephropathy and retinopathy. Blood pressure maintainance to normal is vital.
Dyslipidemia:   This   concerns   with   decreased   high   density   lipoprotein
cholesterol  (HDL),    increased   low   density   lipoprotein   (LDL),   increased
triglyceride  level  and increased lipoprotein levels center primarily on cardiovascular
complications but also is linked to neuropathy.
Platelet adherence: Patients with diabetes have an increased platelet adherence
and
(PAI-1)   aggregation that can cause significance micro vascular problems. 
Plasminogen activator inhibitor-1 can play a role in altering the blood’s ability to 
clot also.
Smoking: Smoking is a direct risk for increased cardiovascular event in both 
patients
Fat intake: High fat dietary intake enhances the risk for vascular problems in
patients with diabetes.
Obesity: Central or truncal obesity has been linked to atherogenesis, though no
causal relationship is yet established for patients with diabetes.
Alcohol use: Alcohol intake enhances the potential for patients with diabetes to
develop neuropathy.
Complications of diabetes29
Both types of diabetes mellitus may develop complications which are broadly
divided into two major groups.
1. Acute metabolic complications:
These  include  diabetic  ketoacidosis,  hyperosmolar  nonketonic  coma an  n
hypoglycaemia.
Late systemic complications:
These are atheroscelerosis,  diabetic  microangiopathy,  diabetic  nephropathy,
diabetic retinopathy and infections.
Acute metabolic complications
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Metabolic complications develop acutely, while ketoacidosis and hypoglycemic
episodes are primarily complications of Type-1 diabetes. Hyperosmolar non-ketotic
coma is chiefly a complication of Type-2 diabetes.
Diabetic ketoacidosis30
It is a state of accelerated starvation caused by insulin deficiency. Insulin
deficiency  causes excessive  lipolysis and decrease in peripheral utilization of
glucose. Free fatty acids produced from lipolysis are oxidized into ketones in liver due
to elevated glucagons and decreased insulin concentration. Ketosis produces acidosis
which causes further loss of electrolyte, loss of vascular tone and shock. Clinically,
the condition is characterized by anorexia, nausea, vomiting, deep and fast breathing,
mental confusion and coma. Most patients of ketoacidosis recover.
Hyperosmolar non-ketotic coma31
Hyperosmolar non-ketotic coma occurs in elderly Type 2 diabetic patients. It is
caused by severe dehydration resulting from sustained hyperglycemic diuresis. The
loss of glucose in urine is so intense that the patient is unable to drink sufficient
water to  maintain urinary fluid loss. Blood sugar is extremely high and plasma
osmolality is high. Thrombotic and bleeding complications are frequent due to high
viscosity of blood. The mortality rate in hyperosmolar non-ketotic coma is high.
Hypoglycaeia 32
Mainly occur in patients of Type-1 diabetes. This may result from excessive
administration  of insulin missing a meal or due to stress. Hypoglycemic episode
are harmful as they produce permanent brain damage or may result in worsening of
diabetic control and rebound hyperglycemia so called Somogyi’s effect.
2. Late systemic complications33
Systematic complication may develop after a period of 15-20 years in either type
of diabetes. These late complications are largely responsible for morbidity and
premature mortality in diabetes.
Atherosclerosis:
Diabetes   mellitus   of   both   Type-1   and   Type-2   accelerate   the development
of atherosclerosis and are more extensive. More often it is associated with
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complication plaques such as  ulceration, calcification and thrombosis. The cause
for  these accelerate atherosclerotic plaques are possible because of contributory
factors like hyperlipidemia,   reduced   HDL   levels,   non-enzymatic   glycosylation,
increase   platelet adhesiveness, obesity and associated hypertension. In diabetes, the
possible ill effects of accelerated atherosclerosis are easily onset of coronary artery
disease, silent myocardial infarction, cerebral stroke and gangrene of lower extremities.
Diabetic Microangiopathy:   
It is characterized by basement membrane thickening of small blood vessels and
capillaries of different organs and tissue such as the skin, skeletal muscle, eye and
kidney. Increase glycosylation of haemoglobin and other proteins (e.g. Collagen and
basement membrane material) results in thickening of basement membrane. 
Diabetic Nephropathy: 
 Renal involvement is a common complication and leads cause of death.  Four
types of lesions are described in diabetic nephropathy.
1.  Diabetic   glomerulosclerosis   which   includes   diffuse   and   nodular   lesions
of glomerulosclerosis, which is termed as Kimmelstiel – Wilson (KW) lesions.
2.  Vascular lesions those include hyaline arteriolosclerosis of afferent and 
efferent arterioles and atheromas of renal arteries.
3.  Diabetes pyelonephritis and necrotizing renal papillitis.
4.  Tubular  lesion  or  Armanni  –  Ebstein  lesions  characterized  by  development
of glycogen vacuoles in the epithelial cells of proximal convoluted tubules.
Diabetic Neuropathy:  
Diabetic neuropathy may affect all parts of the nervous system but symmetric
peripheral neuropathy is most characteristic. The basic pathologic changes are segment
demyelination, Schwann cell injury and axonal damage. The pathogenesis of
neuropathy   is   not   clear   but   may  be   related   to   diffuse   microangiopathy   as
already explained  or  may  be  due  to  accumulation  of  sorbitol  and  fructose  as  a
result  of hyperglycemia.
Diabetic Retinopathy:
 Diabetic retinopathy is a leading cause of blindness.
There are two Types of lesions involving retinal vessels.
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1. Background
2.   Proliferative
Background  retinopathy  is the  i n i t i a l  r e t i n a   capillary  microangiopathy.
Proliferative  retinopathy  or  retinitis  proliferens  occurs  eventually  due  to  severe
ischemia  and  hypoxia  of   the  retina.   The major pathologic c h a n g e s  a r e  t h e
neovascularisation at the optic disc or along  the retinal veins. Besides retinopathy
diabetes patients are also prone to early development of cataract and glaucoma. 
Infections:
Diabetics have enhanced susceptibility to various infections such as
tuberculosis, pneumonias, pyelonephritis, otitis, carbuncles and diabetic ulcers. This
could be due to various factor such as impaired leucocyte functions, reduced cellular
immunity poor blood supply due to involvement and hyperglycemia per se. 
Mechanisms of hyperglycemia-induced damage34
Four major hypotheses about how hyperglycemia causes diabetic complications 
have generated a large amount of data on specific inhibitors of these mechanisms.
1. Increased polyol pathway 
flux
2. Increased intracellular AGE
3. Activation of protein kinase-
C
4. Increased hexosamine
pathway flux formation.
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1. Increased polyol pathway:
Increase activity of  this  ubiquitous  biochemical  pathway  lead  to  intracellular
accumulation of osmotically active sorbitol and fructose through the action of the
enzyme aldose reductase. A number of mechanisms have been proposed to explain the
potential detrimental  effects  of   hyperglycemia   induced   increases   in   polyol
pathway   flux.   These include sorbitol-induced osmotic stress, decreased Na+/ K+
ATPase activity, increased cytosolic NADH  /   NAD+    and  decreased   cytosolic
NADPH.  Depletion  of  myo-inositol  and impairment  of  Na+    /  K+    ATPase  are
the   associated   disturbances   those   have   been  implicated,  particularly  in  the
pathogenesis of diabetic neuropathy.
2. Increased intracellular AGE Formation
AGEs are found in increased amounts in extracellular structure of diabetic retinal 
vessels and renal glomeruli, where they can cause damage by following mechanisms. 
Intracellular production of AGE p r ecu r so r s   damages  target  cells  by  three  
general mechanisms:
• Intracellular proteins modified by AGEs have altered function
• Extracellular matrix components modified by AGE precursor interact abnormally with
other matrix components and with matrix-receptor (integrins) on cells.
• Plasma proteins modified by AGE precursors bind to AGE receptor on cells such  as
macrophages, inducing receptor-mediated ROS production. This AGE receptor  ligation
activates the pleiotrophic transcription factor NFκB, causing pathologic changes in gene
expression.
Activates protein kinase C - β in endothelial cells. This alters vascular
permeability and  increases  basement membrane synthesis (an important early
histological feature of the micro vascular complications of diabetes) and pathological
changes results.
↑ Glucose → ↑ Di acyl glycerol  → ↑ Protein Kinase C - β
Secondary increase in the expression of growth factors with effect on vascular
permeability and may contribute to neovascularization in the retina.
4. Increased hexosamine pathway flux
24 | P a g e
[Type text]
In this  mechanism glucose is shunted into the hexosamine   pathway.   In   this
pathway,  fructose-6-phaosphate  is  diverted  from  glycolysis  to  provide  substrates
for  reactions that required   UDP-N- acetyl  glucosamine, such as proteoglycan
synthesis and the formation of O-linked glycoproteins.  Inhibition of the rate limiting
enzyme in the conversion of glucose to glucosamine, blocks hyperglycemia-induced
increases in the  transcription of both TGF- α and TGF-β1. This pathway has
previously been shown to play an important role in hyperglycemia-induced and fat-
induced insulin resistance.
Treatment of diabetes mellitus
Treatment of diabetes mellitus involves changes in lifestyles and pharmacologic
intervention with insulin or oral glucose lowering drugs. In Type-1 diabetes mellitus,
the primary focus is to replace insulin secretion; lifestyle changes are required to
facilitate insulin therapy and optimize health. For most patients with Type-2 diabetes,
changes in lifestyle are the cornerstone of treatment, particularly in the early stages
of the disease.
Pharmacologic intervention is a secondary treatment strategy.32
Drugs for Type-1 diabetes mellitus32
Insulin remains the mainstay of therapy for the treatment of Type-1 diabetes.
Various forms of insulin dosage forms are available.
Insulin Types
Four types of insulin are classified according to the three criteria.
1.  Onset: How quickly the insulin starts to work after it is injected.
2.   Peak time: The period of time when insulin is most effective in lowering
blood sugsr levels.
3.   Duration: How long the insulin is most effective in lowering blood sugar
levels.
Only NPH insulin is mixed with regular insulin to allow the action of both types
of insulin at the same time. Other types of insulin cannot be mixed together and
may  required separate  injections.  Insulin  is  indicated in the following conditions  in
diabetes.
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                                         Table: Insulin types
Oral hypoglycemic agents32
Type-2 diabetes patients requiring insulin are those cases who have failed to
achieve optimal glycemic control on maximal doses of oral agents. In this situation
addition of evening or bedtime intermediate acting insulin to the oral agent is an easy
and highly effective  method  to   regain  optimal   glucose   control.   When evening
insulin  is  added, total dose of oral agent can be given in the   morning before
breakfast. In this  manner, evening insulin can be used to control early morning
hyperglycemia whereas oral agents exert their effects on day time glycemia.
TARGETED DRUGS THERAPY FOR TYPE-2 DIABETES
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Insulin preparation Onset (h) Peak (h) Duration (h)
Short acting
Lispro < 0.25 0.5 – 1.5 4 –6
Intermediate acting
NPH Lente 2 -4 6 -10 14 -18
Long acting
Ultralente 6 -10
10 -16
20 -24
Combination
75 % NPH, 25 % Regular
70 % NPH, 30 % Regular
50 % NPH, 50 % Regular
0.5 -1
0.5 -1
0.5 -1
Dual
 Dual
 Dual
14 -18
14 -18
14 -18
[Type text]
Table: Targeted drugs therapy for Type-2 diabetes
1.  Insulin secretogogues:
a.  Sulphonylureas:
First generation :Tolbutamide, Chlorpropamide, Acetohexmide, 
Tolazolamide
Second generation : Glibenclamide, Glipizide, Gliclazide, Glimeperide
  b.   Meglitinides : Repaglinide
2.  Insulin sensitizers : Biguanides, Thiazolidines
3.  α-glucosidase inhibitors: Acarbose, Miglitol
4.  Indian drugs : Guar gum, Fenugreek seeds
Sulphonylureas
Sulphonylureas have been the mainstay in the treatment of Type-2 diabetes and
functions by  stimulating insulin secretion from pancreas; hence they are called
insulin secretogogues. The net effect is increased responsiveness of β-cells of pancreas
resulting  in  more  insulin.  1st  generation   sulphonylureas  have  a   lower   binding
affinity  to sulphonylureas  receptor  and  must  be  given  in   higher  doses  than
2nd   generation sulphonylureas.
Mode of action: The sulphonylureas stimulate insulin secretion through a direct
effect on the pancreatic β-cells. They bind to sulphonylurea receptor (SUR) on these
cells, which is a component of the   trans  membrane complex that houses the ATP-
sensitive potassium channels   (K-ATP  channels)   binding   of   the   sulphonylurea
closes   K-ATP   channels,  reducing potassium efflux and favoring membrane
depolarization. In turn, depolarization  opens  voltage-dependent  calcium  channels,
increasing  calcium  influx,  raising  intracellular  calcium  concentrat ions and
activating calcium dependent  proteins  that  control the release of insulin
granules. In this way, the sulphonylureas lead to a prompt release of pre-formed
insulin granules adjacent to the plasma membrane (first phase insulin release). This
class of drug also seems to exert some weak extra pancreatic effects which suppress
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hepatic gluconeogenesis and potentiate insulin mediated glucose uptake into  muscle
and adipose tissue.
Clinical use of sulphonylureas
Indications: 
Patients  with  Type-2  diabetes  inadequately  controlled  by  non  pharmacological
measures of other types of oral antidiabetic agents.
Type of therapy: Monotherapy or in combination with other antidiabetic agents
except other insulin-releasing agents.
Treatment schedule: A low dose to begin with escalated slowly. Schedule
should be adjusted if necessary to minimize the risk of hypoglycemia. Maximum
effect may be achieved before the maximum permitted dose is reached.
Cautions and contraindications: Should be used cautiously in patients with
hepatic or renal disease of porphyria.
Side effect: Occasional, usually transient, sensitivity reactions. Chlorprapamide
can  lead  to  facial  flushing  after  alcohol  has been  consumed  rarely,  it  causes
hyponatremia.
Adverse effects: Risk of hypoglycemia, especially with high doses of longer
acting preparations.
Note: Always start with a low dose of sulphonyl urea. Monitor blood glucose by
an appropriate method and increase dosages at 2-4 week interval as necessary until
the glycemic target is achieved.
Non-Sulphonylureas
Brief history:  The non sulphonyl urea portion of glibenclamide, a benzamido
compound termed  meglitinide was  shown to stimulate insulin secretion in the  early
80’s.
Mode of action: The mechanism through which benzamido prandial insulin
releasers  stimulate insulin   secretion is essentially the same as that of the
sulphonylureas. These drugs also bind to the SUR on the plasma membrane of the β-
cell, but at a different site.  This   binding   closes   the   ATP-sensitive   potassium
channel,   leading   to   depolarization,  voltage-dependant   calcium   influx,   and
activation  of  calcium  dependant  proteins  that control insulin release.
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Clinical use of Repaglinide
Indications:  Patients  with  Type-2  diabetes  inadequately  controlled  by  non
pharmacological measures or other Types of oral agents that do not stimulate
insulin secretion. Patients prone to interprandial hypoglycemia on a sulphonylurea.
Type of therapy:  Monotherapy or in combination with other antidiabetic agents
(except other insulin-releasing agents).
Cautions and contraindications: Should be used with cautions in patients with
hepatic or severe renal disease.
Side effects: Occasionally sensitivity reactions, usually transient.
Adverse reactions and precautions: Risk of hyperglycemia. Possible 
interactions with nerythromycin, rifampicin and some antifungal agents.
Futere therapies to improve insulin secretion
New sulphonylurea formulations:
A micronized formulation  of  glibenclamide  (glyburide)  introduced  in  the  US
increases the rate of absorption and enables an earlier onset of action. A longer
acting  (extended  release)  formulation  of  glipizide  (glucotrol  XL)  has  also  been
introduced.
A modified release formulation of gliclazide (diamicron MR) has been developed.
While the  duration of action of glicazide is unchanged; this new formulation uses
a  hydrophilic matrix to match   progressive delivery of gliclazide with the
hyperglycemic  profile. Improved bioavailability enables once  daily dosing while
reducing the dosage from 80 mg per tablet to30 mg per tablet.
Novel insulin releasers
A  potential  future  approach  to  synchronizing  insulin  secretion  with  meal
consumption   involves   the   intestinal   hormone   Glucagon-Like   Peptide-1   (7-36
amide)  (GLP-1).   GLP-1   potentiate   nutrient   stimulated   insulin   secretion   via
receptors   in   the  pancreatic β-cell membrane which activate cyclic adenosine
monophosphate (cAMP) and  this increases the insulin response to a meal. It also
enhances proinsulin biosynthesis and  may  additionally  slow  gastric  emptying  and
induce satiety.
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A further novel approach to enhancing insulin secretion involves succinate esters
which enhance  the activity of the Krebs cycle in the β-cell. This stimulates
proinsulin biosynthesis and insulin secretion. However, succinate esters can serve as a
nutrient fuel in a range of tissues and provide a substrate for gluconeogenesis. Thus,
this approach can only be exploited if the succinate esters are targeted predominately at
β-cells.
Biguanides
Metformin  is  the  only  biguanide  available.  It  is  less  widely  used  than  the
sulphonylureas because of a higher incidence of side effects, particularly
gastrointestinal symptoms.
Mode of action: Metformin has a variety of  metabolic effects. It acts partly by
improving insulin action and partly by effects that are not directly insulin dependent.
Metformin  lowers blood glucose  concentrations without causing overt
hypoglycemia. Its clinical efficacy requires the presence of insulin, but the drug does
not stimulate insulin release and typically causes a small decrease in basal insulin
concentration in hyperinsulinemic patients.
It reduces hepatic gluconeogenesis mainly by increasing sensitivity of insulin.
Additionally it reduces the hepatic extraction of certain gluconeogenic substrates (such
as  lactate) and opposes the effects glucagons. It decreases the rate of hepatic
glycogenolysis, and the activity of hepatic glucose-6-phosphatase.
Insulin stimulated glucose uptake and glycogen formation in skeletal muscles are
enhanced by metformin. These involved increases movement of insulin sensitive
glucose  transporters  into  the  cell  membrane  and increased  activity  of  glycogen
synthase.
Metformin  also  acts  in  an  insulin-independent  manner  to  suppress  fatty  acid
oxidation and reduce triglyceride levels in hypertriglyceridemic patients. This reduces
the energy supply for gluconeogenesis and improves the glucose cycle.
Indications:  Patients  with  Type-2  diabetes  inadequately  controlled  by  non
pharmacological measures or other oral antidiabetic agents.
Type of  therapy:  Monotherapy  or  in combination  with  any  other  antidiabetic
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agents.  Treatment schedule: Metformin should be taken with meals and dose
escalated slowly to a maximum of 2550 or 3000 mg/day.
Cautions and  contraindications:  Renal   and   hepatic   disease,   cardiac   or
respiratory disease   or   any   other   hypoxic   condition,   severe   infections,   alcohol
abuse,  history  of acidosis, intravenous radiographic contrast media.
Side effects:  Gastrointestinal symptoms (e.g. diarrhoea), metallic taste, possibly
educed absorption of vitamin B and folic acid, intravenous radiographic contrast media.
Adverse reactions:  risk  of  lactic  acidosis  if  contraindications  breached  risk  of
hypoglycemia with combination therapy.
Precautions: Contraindications should be observed, especially renal function  (e.g.
creatinine level): interacts with cimentidine.
α -Glucosidase inhibitors
Mode of action: α-Glucosidase  enzymes in the brush border of the small
intenstine,  along with pancreatic α-amylase are responsible for the hydrolysis of
complex starches, oligosaccharides, trisaccharides and disaccharides. Acarbose, an α-
Glucosidase and α- amylase inhibitor, works by  reducing the rate of complex
carbohydrate digestion and subsequent absorption of glucose, thereby lowering post
prandial glucose excursions in patients with diabetes. Acarbose is particularly
effective for patients who experience postprandial hyperglycemia. Meglitol is another
α-Glucosidase inhibitor that works similarly to acarbose and like wise is effective in
controlling postprandial hyperglycemia.
Indications:  For  patients  with  Type-2  diabetes  inadequately controlled  by non-
pharmacological measures or other antidiabetic agents.
Treatment schedule: Should  be  taken  with  meals  rich  in  digestible
complex carbohydrate. Dose should be titrated slowly
to be compatible with meals.
Cautions and contraindications:  renal   and   hepatic   disease,   history   of
chronic intestinal disease.
Adverse reactions: Gastrointestinal disturbances are occasionally severe, very
rarely associated with abnormal liver function.
Adverse effects: The most common problems experienced with the α-Glucosidase
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inhibitors are gastrointestinal side effects.
Thiazolidinediones
Mode of action: These drugs (also called TZD drugs, glitazones or PPARγ
agonists) bind and   activate   peroxisome   proliferators   activated   receptor   γ,   a
nuclear   receptor   that regulates   the   expression   of   several   genes   involved   in
metabolism   and   worked   by enhancing the action of endogenous insulin. Insulin
sensitivity (mainly in adipose tissue)  is improved only in patients with insulin
resistance: plasma insulin concentrations are not increased and hypoglycemia is not a
problem. Its main action is on muscle tissue, where it increase glucose disposal, and to
a lesser degree in the liver, where it decreases hepatic glucose production.   To other
thiazolidinediones, rosiglitazone and pioglitazone, act similarly to troglitazone. 
Clinical use of the Thiazolidinediones
Indications: Type-2 diabetic patients inadequately controlled by non-
pharmacological measure or other antidiabetic agents.
Type of  therapy:  Monotherapy  or  in combination  with  any  other  antidiabetic
agents. Treatment schedule:  Pioglitazone (15 or 30 mg/day), rosiglitazone (2 or 4
mg/day). Dose  should  be  escalated   gradually  upto  a  typical  maximum  of  45
mg/day  for pioglitazone and 8 mg/day for rosiglitazone.
Cautions  and  contraindications:   Congestive  heart  disease,  heart  failure,
oedema, anaemia, impaired liver function.
Side effects: Fluid retention, increased plasma volume, reduced haematocrit,
decreased haemoglobin, ovulation in polycystic ovarian syndrome.
Adverse effect: Risk of oedema and anaemia, risk of hypoglycemia with
combination therapy.
Precautions:   Check   for   contraindications,   monitor   liver   enzymes   (e.g.
alanine transaminase), and potential effect on oral contraceptive activity (pioglitazone).
Animal models for experimental Diabetes Mellitus 33, 34 There are many
advantages of using animals models in research work on diabetes as various aspects of
the disease like the etiology, its multifactorial genetics, pathogenesis of the disease and
its complication can be explicitly understood. Secondly, it also helps in  the
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development and evaluation of newer agents for the treatment of diabetes. However,
there are some limitations in the use of animal model for studies on diabetes.
Induction of diabetes in animals can be carried out by various ways – by using
different   chemical diabetogenic agents, surgically by partial pancreatectomy, by
viral induction and genetic manipulation by selective in breeding.
Various diabetic chemicals
Induction of diabetes by various chemical diabetogenic agents is also dependent
on the species, the strain, sex and the diet of the animals. Variations in susceptibility
have also been observed amongst male and female mice of same strain, males being
more susceptible  to  insulin  dependent  diabetes  mellitus  (IDDM)  than  females.
Types of diabetes produced depend on the amount of diabetogenic agent used.
1. Alloxan34
Diabetogenic action of alloxan is mediated by reactive oxygen species. Alloxan
and the product of its reduction, dialuric acid, establish a redox cycle with the
formation-of  superoxide  radicals. These radicals undergo dismutation  to  hydrogen
peroxide.  Thereafter highly reactive hydroxyl  radicals are formed by the Fenton
reaction. The action of reactive oxygen species with a simultaneous massive increase
in cytosolic Ca+2 concentration  causes rapid destruction of β-cells. The action of
alloxan in the pancreas is preceded by its rapid uptake by the β-cells. Since alloxan
exhibits a high affinity to th SH-containing cellular compounds, reduced glutathione
(GSH),   cysteine   and   protein  bound sulfhydryl groups (including SH-containing
enzymes) are very susceptible to its action. The reaction between alloxan and dialuric
acid is a process in which intermediate alloxan radicals (HA•) and an unidentified
“compound 305” (maximum absorption at 305 nm) is formed. Alloxan is converted
into unstable dialuric acid which is then re oxidised back to alloxan. This reaction
establishes a redox cycle for the generation of superoxide  radicals and also
accompanied by reduction of oxygen to the OFR, O2, and H2O2. The latter, through
a Fanton Type reaction in the presence of transition metals generates the highly toxic
OFR, OH. Increased  production  of  OFR  in  the  islets,  together  with inadequate
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defence  makes the β-islet cells  susceptible   to alloxan.  Alloxan  induces  membrane
lipid  peroxidation  and  extensive  DNA  strand  breakage  in  these  cells.  In normal
non fasted animals, the blood glucose level after alloxan injection fluctuates in a
triphasic pattern.
Triphasic response of alloxan
1.   Early hyperglycemia of short duration (about 1-4 h) due to a sudden short
lasting decrease or cessation of insulin release and a direct glycogenolytic effect on
the liver.
2.   Hyperglycemia phase lasting up to 48 h and often resulting in convulsion
and death (which may be prevented by treatment by glucose) due to uncontrolled
leakage of insulin from the damaged cells.
3.  Chronic diabetes phase, consequence of insulin lack histologically only a few
β-  cells if any, are detectable in animals with fully developed alloxan diabetes.
Exogeneous insulin readily restores normal blood glucose level.
2. Streptozotocin35
Streptozotocin  [STZ,2-deoxy-2-{3-(methyl-3-nitrosoureido)-Dglucopyranose}]  is
synthesized by streptomycetes achromogenes and is used to induce both Type-1 and
Type-2. It is freely soluble in water, unstable at room temperature and has to be
stored below -20 oC.
Streptozotocin induces diabetes in almost all the species. Diabetes dose varies
with the species and the optimal dose required to produce diabetes in rat was found to
be (50 – 60 mg/kg i.p. or i.v.), in mice (175-200 mg/kg i.p. or i.v.) and in dogs (15
mg/kg,  for 3 days). Due to its low stability the rapid i.v. injection appears to be the
best route of administration. STZ induces diabetes in hamster, monkey and guinea
pigs. STZ diabetes can be induced by two ways either by single injection of STZ or
by multiple low dose injection of STZ. Like alloxan, it  shows triphasic fluctuation
pattern in diabetes.
Initial  hyperglycemia  is  observed  by  1  h  after  the  injection  followed  by
hyperglycemia and again a hyperglycemia state at 48 h, the elevated blood glucose
level is observed by 48-72 h (peak effect) and is maintained thereafter.
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Different mechanism  of  action  on  the  β-cells  destruction  by  STZ  have  been
proposed. Its  main actions through free redical generations. Other report proposed
that STZ  exerts  lethal  damage  by  alkylating  DNA  or  its  phosphate  backbone  as
well   as glycolytic   or   mitochondria   enzyme.   STZ   also   influence the immune
system by suppressing the T-cell function associated with atrophy of   the   thymus
and peripheral lymphoid tissue. Like alloxan, STZ also induces OFR induced lipid
peroxidation and DNA strand breaking in pancreatic islet cells.
Streptozotocin enters the β-cell via a glucose transporter (GLUT 2) and cause
alkylation of DNA. DNA damage induces activation of poly ADP-ribosylation leads
to depletion   of  cellular   NAD+     and ATP.   Enhanced   ATP   dephosphorylation
after streptozotocin  treatment  supplies  a  substrate  for  xanthine  oxidase  resulting
in   the  formation of superoxide radicals. Consequently, hydrogen peroxide  and
hydroxyl radicals  are also generated. Furthermore, streptozocin liberates toxic
amounts of  nitric oxide  that inhibits aconitase  activity and  participates  in  DNA
damage.
Alloxan Streptozotocin
1. Maximum  blood  glucose  levels
during phase of acute 
hyperglycemia occur in 45 
minutes.
2.  Liver glucogen depletes faster.
3.  Elevated   insulin   levels   during   
hypoglycemia phase.
4.    Hypoglycemia less severe.
5.   Sensitive to insulin
6.   Mortality rate is 37%.
  7. Reversible after 3 months.
1. Maximum blood glucose
level
during phase of
acute hyperglycemia
occurs in
120 minutes.
2. Liver glucogen depletes slowly.
3. Elevated  insulin levels during 
hypoglycemia phase.
4.       More severe.
5. Sensitive to insulin.
6. Mortality rate is 8%.
7. Irreversible.
          Table: Comparison of alloxan and streptozotocin diabetes
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3. Lithium salt34
It has been shown to inhibit glucose stimulated insulin release in rats, after either
in vitro or in vivo administration leading to glucose intolerance. Lithium stimulates
the α- adrenocepters leading to increase in plasma glucose level and inhibits the
release of insulin from the pancreatic islet calls. I.V. infusion of lithium at a dose of
4 mg/kg into the jugular vein of anaesthetized rats produced an elevated blood glucose
level within 30  minutes   and   7-8   nmol/l   and   by   2   h   the   animal   became
normoglycemic.  This hyperglycemia effect on the sympatho– adrenal function, both
directly and indirectly, leading to  decreased release of insulin from the β-cells of the
pancreas
4. Cyclosporine A (CsA)
Cyclosporine A has effects on the pancreatic endocrine functions and has been
reported to cause hyperglycemia in humans, dogs and several different strains of rats.
The exact mechanism of this hyperglycemic action is not known but in vivo studies
suggest that CsA administered orally at a dose of 40 mg/kg to Wistar rats for 7 days
produced significant increase in fasting blood sugar levels.
5. Miscellaneous agents36
The other agents used for induction of NIDDM induce adrenaline (0.1 mg/kg,
s.c.) administered in rabbits, the peak glycemia effects was noticed at 1 h and lasted up
to 4 h. The increase in blood sugar levels was found to be 120-150 mg/100 ml.
Oral  hypoglycemic agents can be screened by this method. Diabetes can also be
induced in  animals with the chelating agents 8-hydroxyquinoline.
Diphenylthiocarbazine EDTA has  been  reported  to  be  diabetogenic  in  partially
depancreatized rats.  Injection of an antiserum made against ox insulin in guinea pigs
or sheep caused diabetes in mice.
Administration of thiazides, chlorothiazides, hydrochlorothiazides, diazoxide and
furosemide  produced hyperglycemia and glucosuria in experimental animals,
including rabbits, rats and mice.  Diazoxide was found to be more effective either
alone or in
combination with other drugs.
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• Ethyl Alloxan 53-130 mg/kg in rat
• Oxime & Dithizone 53 mg/kg in rabbit
• Sodium Diethyldithiocarbonate 0.5-1 gm/kg in rabbit
• .  Potassium Xanthate 200-350 mg/kg in rabbit
• Uric Acid 1 gm/kg in rabbit
Non-insulin dependent diabetes mellitus (NIDDM) resembling animal models
By altering the dose and the day of the STZ injection, the n-STZ models exhibit
various stages  of Type-2 diabetes mellitus, such as impaired glucose tolerance,
mild, moderate and severe hyperglycemia.
Neonatal STZ-induced rat (n-STZ) model of Type 2 diabetes mellitus model is
generated by   injecting Wistar rats on the day of their birth (n0=birth)
intravenously (sapheneous vein) or intraperitoneally with 100 mg/kg of STZ. Also, the
n-STZ rat model is developed by varying the day of the STZ injection after the birth,
such as 2nd day or 5th day  of  the  birth,  and  these  are  alternatively   called   n2-
STZ  and  n5-STZ  models respectively.
The rats treated with STZ on the day of birth, exhibit insulin deficient acute
diabetes mellitus 3-5 days after birth. They showed high plasma glucose and about
93% decrease in plasma insulin and high plasma glucagon content.  It was found that
only by 8 weeks of age and thereafter n0-STZ rats showed mild hyperglycemia.
Sprague-Dawley pups were injected intraperitoneally on the 2nd day after birth
with 90 mg/kg STZ and on 1.5 days after birth with 120 mg/kg STZ. By 6 weeks of
age these animals showed basal hyperglycemia and abnormal glucose tolerance. The
above two animal models are based mainly on β-cell deficiency and these models
are  useful for evaluating the effect of β-cell deficiency in the development of
NIDDM.
NIDDM animal models can also be prepared by neonatal alloxan induced diabetes
by injecting alloxan 200 mg/kg body weight i.p. to neonates of 6 days old. Non
fasted  blood sugar is determined after 8 weeks. The hyperglycemia produced is
stable upto 6 months.
Insulin dependent diabetes mellitus (IDDM) resembling animal models34
IDDM  both  in  human  beings  and  in  animals  models  of  IDDM,  is  due  to
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destruction of  β-islet cells, ultimately leading to an absence or decreased secretion
of  insulin, the destruction of the β-cell can be brought about by viral induction
injection of diabetogenics or by introduction of transgenes. Streptozotocin and alloxan
were found to  be more selective in β-cell destructive than other chemical   like
ascorbic acid and its derivative and uric acid. These substances have also been
referred to as β-cytotoxic substance or simply β-cytotoxic with the implication that
the actions are restricted to the β-cell of the islet of Langerhans.
Pancreatectomy in dogs and rats
Either by total pancreatectomy or partial excision of pancreas, diabetes can be
induced  in  dogs, cats and rats. The diabetes produced is very severe and persist at
maxium intensity.
Virus induced diabetes
Juvenile-onset (Type-1) diabetes mellitus may be due to virus infection and β-cell
specific   auto-immunity.   The   D-variant of  encephalomyocarditis   virus   (EMC-D)
selectively infects and destroys pancreatic β-cells in susceptible mouse strains similar
to human insulin dependent diabetes. Adult male ICR swiss mice are susceptible to
the diabetogenic effect of the D-varient of encephalo myocarditis virus in contrast to
adult CH/HCT male mice, which are relatively resistant.
Genetically diabetic animals
Several animal species, mostly rodents were described to exhibit spontaneously
diabetes   mellitus on a hereditary basis. Due to difficulty in breeding severely
affected animals only a few species are used on a broader scale, such as Chinese
hamster, obese mice, the obese hyperglycemic Zucker rat and various substrains of KK
mice. Spontaneously diabetic animals
1.  Spontaneously diabetic rats
2.  Spontaneously diabetic mice
1. Spontaneously diabetic BB rat:
A BB rat is model of spontaneous diabetic associated with insulin deficiency due 
to auto-immune destruction of pancreatic β-cells.
2. WBN / KOB rat:
Spontaneous hyperglycemia glycosuria  and  glucose  intolerance  have  been 
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observed in aged male of an in-bred Wistar strain.
3. Cohen diabetic rat:
Characterized  by  hyperglycemia,  glycosuria  and  hyperinsulinemia  with  late
development   of hypoinsulinemia, insulin resistance and a decrease in the number
and sensitivity of insulin receptors.
4. Zucker-Fatty rat:
This is a classic model of hyperinsulinemic obesity. These rats manifest mild
glucose intolerance, hyperinsulinemia and peripheral insulin resistance similar to human
NIDDM.
Chapter: II
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          A study of Evaluation of aqueous extract of Cyperus rotundus roots on diabetic
complication in Alloxan induced diabetic rats.
Objectives of the study:
To evaluate the Aqueous extact of Cyperus rotundus in the management of type-II
non-insulin dependent diabetes mellitus complications. The study was conducted by the
following objectives.
1. To prepare aqueous extraction of Cyperus rotundus root 
2. To study the phytochemical screening of ethanolic extract Cyperus rotundus root
3. To study the acute oral toxicity  of Cyperus rotundus root
4. To study the diabetic complication of aqueous extract of Cyperus rotundus root in 
rats by the following model
 Alloxan induced diabetic rats
         Parameters to be studied:
1. Assessment of thermal hyperalgesia and cold allodynia 
• Hot plate method
• Tail immersion (Hot water and cold water)
2. Estimation of serum biochemical parameters
SGOT
SGPT
 ALP
Creatinine
Urea 
uric acid
3. Histopathology of pancrease
Chapter: III
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1. Nagulendran kr et al45 in (2007) has studied, In Vitro Antioxidant Activity and
Total Polyphenolic Content  of Cyperus rotundus Rhizomes 
2. Gupta MB et al  46 in (1971) has studied Pharmacological studies to isolate the
active constituents from  Cyperus rotundus  possessing anti-inflammatory,  anti-pyretic
and analgesic activities. 
3.  Uddin  SJ  et  al47 in  (2006),  has  studied  Antidiarrhoeal  activity  of  Cyperus
rotundus.
4. Puratchikody A et al48 in (2006), had studied Wound healing activity of cyperus
rotundus linn.
5. KemprajVivek et al 49 in (2008), had studied   Ovicidal and larvicidal activities
of Cyperus giganteus Vahl and Cyperus rotundus Linn .
6.  Kilani Soumaya, et al50 had studied Investigation of extracts from (Tunisian)
Cyperus rotundus as antimutagens and radical scavengers.
7.  Komai KV et al51 in (1975), has studied Chemical properties and behaviour of
polyphenolic substances in Cyperus rotundus.
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                                        IV.PLANT PROFILE 
Botanical Name :         Cyperus rotundus
Scientific Classification
Kingdom  :      Plantae
(Unranked)      :     Angiosperms
 (Unranked)     :     Monocots
 (Unranked)     :     Commelidins
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  Order             :     Poales
 Family            :    Cyperaceae
  Genus            :    Cyperus
  Species :    C.rotundus 35
General
Cyperus rotundus (Cyperaceae) is a traditional herbal medicine used as analgesic,
sedative  antispasmodic,  antimalarial,  stomach  disorders  and  to  relieve  diarrhea36.
Cyperus rotundus is a Perennial Plant that  reach a height  up to 140 cm. the leaves
sprout  in   three  from  the  base  of  the  plant,  around  5–20 cm  long.  The  flowers
stems have a triangular cross-section. The flower is Bisexual and has three stamina and
a three-stigma carpels, with the flower head have 3-8 unequal rays. The fruit is a three-
angled achene. The root of a young plant initially forms white, fleshy rhizomes, up to
25 mm, in chains. Some rhizomes grow upward in soil, form a bulb-like structure from
which new shoots and roots grow37. 
Distribution and habitat:
Cyperus rotundus is one of the most invasiveweed known, having a worldwide 
distribution in tropical and temperate regions. It has been called "the world's worst 
weed" 38
Common Indian Names
Gujarati:     Motha
Hindi:          Motha, Mutha
Canarese:   Koranarigadde, Tungegaddo, Tungehullu
Marathi:      Bimbal, Nagarmotha, Motha
Sanskrit:      Bhadramusta, Granthi, Kachhda, Mustako, Sugandhi-granthila
Tamil:           Korai 
Telugu:         Tungagaddi .
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Morphology: 
A perennial, stolaniferous, rhizomatus, halophytic sedge. Rhizome many, slender;
Tuber-white, succulent when young, hard and black when mature;stem-leafy at base
arising from a tuber. Culm-dark green, glabrous. Leaf dark green above, with reddish
brown sheaths, clustered at the base of stem. Inflorescence 3-9 spreading rays bearing
tassels of few, large spikelets; spikelet 20-40 flowered, red brown to almost black. Fruit
oblong ovate39.
ACTIVE CHEMICAL CONSTITUENTS:
Cyperus  has  numerous  chemical  constituents,  but  the  main  active  components
appear to be the sesquiterpenes. These are aromatic, spicy tasting molecules. Among
the  main  sesquiterpenes  identified  in  cyperus  rhizomes.  α-cyperone,  β-selinene,
cyperene, cyperotundone, patchoulenone, sugeonol, kobusone, and isokobusone.
Cyperus  also  contains  other  terpenes,  such  as  the  commonly  occurring  plant
component pinene (a monoterpene), and several derivatives of the sesquiterpenes, such
as cyperol, isocyperol, and cyperone40 
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PHARMACOLOGYCAL USES:
The Cyperus rotundus rhizomes are pharmacologically used for promoting, nervine
tonic, diuretic, antiperiodic, and traditionally used to treat diarrhoea, dysentery, leprosy,
bronchitis,  amenorohoea,  dysmenorrhoea,  renal  and  vesical  calculi,  ophthalmic
disorders, blood disorders and general debility41 Pharmacological studies rvealed the
rhizomes as analgesic, anti-inflammatory, antipyretic42. This antidibetic activity can be
attributed to its antioxidant activity as it showed the strong DPPH radical scavenging
action  in  vitro43.  The  Antibacterial  activity  of  Cyperus  oil  was  studied  for  various
microorganisms  (Staphylococcus  aureus,  Klebsiella  pneumoniae,  Proteus  vulgaris,
Streptococcus  pyogenes,  Eschirichia  coli and  Pseudomonas  aeruginosa,   activity
against gram-positive bacteria44.
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                    Materials
and Methods          
   
                                        
   V. MATERIAL AND METHODS
Borosilicate  Soxhlet  extractor,  Alloxan  monohydrate  (Sigma  Aldrich,  usa),
Biochemical  Analyser-ROBONIK (prietest  easylab,  Mumbai),  ROBONIC diagnostic
kit  (creatinine,  total  protein,  urea,  uric  acid)  Centrifuge  Biofuse  pico  (Heraeus),
electronic digital weighing (Apex), EDDY’s Hot plate analgesometer MK-111, (Sisco,
Thane, Maharastra), Glucose check monitoring system (Aspen diagnostics ltd, Delhi,
India.) micropippet.
DRUGS AND CHEMICALS
Alloxan  monohydrate  (Sigma  Aldrich,  USA),  Metformin  (Alembic  Pharma)
Chloroform (Fisher scientific), Diethyl ether (Fisher scientific) and all other chemicals
were used AR grade.
 PLANT MATERIAL
Plant Authentication
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Plant sample of Cyperus rotundus  roots were collected in march 2013  from S.V.
University, Tirupathi, India. Verified  by prof. Dr.M. Madhava Shetty Department of
Botony.
Preparation of extract:
Plant material of Cyperus .rotundus dried roots were collected and powdered by pulverize.
The powdered drug then was passed through sieves no. #44 and used  for extraction process.
Approximately 100 gm of powder was placed in soxhlet extractor with water 400 ml (1:4) for
72 hrs. the final yield is found to be 20.2 gm. The extract was dried and concentrated at 45 c in
the water bath and residue of extract was analysed for experiment. The extract was dissolved
with distill water and given orally at the time of animal dosing.
 Experimental animals
 The Wister albino rats of either sex (200-250g) were obtained from the central
animal  house  of  Sigma  institute  of  clinical  research  &  administration  pvt.  ltd,
Hyderabad. Animals were housed at a temperature of 24±2°C and relative humidity of
30-70%. A 12:12 hr light :dark cycle was followed. All animals had free access to water
and standard pellet  laboratory animal diet.  Animals were acclimatized to laboratory
conditions  before  the  experiment  procedure  used  in  this  study  were  reviewed  and
carried out in with that described by Zimmerman et al(1). Institutional Animal Ethics
Committee (769/2010/CPCSEA) approved the study protocol.
Acute oral toxicity study52 
Procedure: Acute  toxicity  studies  were  performed  according  to  OECD-423
guidelines  category IV substance  (acute  toxic  class  method).  Albino mice  (n=3)  of
either sex selected by random sampling technique were employed in this study. The
animals  were  fasted  for  4  hrs  with  free  access  to  water  only.  The  root  extracts  of
Cyperus. rotundus were administered orally with maximum dose of 2000 mg/kg body
weight. The mortality was observed for three days. If mortality was observed in 2/3 or
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3/3 of animals, then the dose administered was considered as a toxic dose. However, if
the mortality was observed only one mouse out of three animals then the same dose
was  repeated  again  to  confirm  the  toxic  effect.  If  mortality  was  not  observed,  the
procedure was then repeated with higher dose (Organization for economic Co-operation
and development, 2001).
Results
The plant root extracts of Cyperus rotundus didn’t shown any mortality and toxicity
even at highest dose of 2000 mg/kg body weight employed. The present research study
was carried out using two different doses (low and high) aqueous extract’s of Cyperus
rotundus such as  200 and 400 mg/kg body weight for diabetic complication.
Toxicity record sheet: Toxicity record sheet is shown as follows for the Cyperus 
rotundus 
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Acute Toxicity Record Sheet of Cyperus rotundus
Title: Evaluation of LD50  Cyperus rotundus 
Drug: Cyperus rotundus                                              Dose: 2000 mg/kg BW                   Species: Albino mice Sex: Male & 
Female
     Date:                                                                                                                                                                     Duration: 24 
hours
S.no. code Toxicity Time  Of  
Death
Observation
Onset Stop Skin 
colour
Eyes Res
p
CNS Tre Con Sali Dia
h
Slee
p
Leth Co
m
1
.
ECR x x x x x x x X x x x x x X
(*TRE-Tremor, CON-Convulsions, SALI- Salivation, Diah - Diarrhea, LET-Lethargy)                      x = Negative,  = Positive
AECR: Aqueous extract of Cyperus rotundus
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Qualitative chemical test53:
Preliminary phyto chemical studies:  Aqueous extract of the plant of root of
Cyperus rotundus  were subjected to chemical  tests for the identification of their
active constituents.
4.2.3 Tests for carbohydrates and glycosides
A small quantity of the extract was dissolved separately in 4 ml of distilled 
water and filtered.  The filtrate was subjected to Molisch’s test to detect the presence
of carbohydrates.
A. Molisch’s Test
Filtrate was treated with 2-3 drops of 1% alcoholic α-naphthol solution and 2ml
of con. H2SO4 was added along the sides of the test tube. Appearance of violet
coloured ring at the junction of two liquids shows the presence of carbohydrates.
Another portion of the extract was hydrolysed with HCl for few hours on a water
bath and  the hydrolysate was subjected to Legal’s and Borntrager’s test to detect
the presence of different glycosides.
B. Legal’s Test
To the  hydrolysate,  1ml  of  pyridine  and  few drops  of  sodium nitroprusside
solution were added and then it was made alkaline with sodium hydroxide solution.
Appearance of pink to red colour shows the presence of glycosides.
C. Borntrager’s Test : Hydrolysate was treated with chloroform and then the
chloroform layer was separated.  To this equal quantity of dilute ammonia solution
was  added.  Ammoniacal  layer  acquires  pink  colour  showing  the  presence  of
glycosides.
4.2.4 Tests for alkaloids: A small portion of the methanol extract was stirred 
separately with few drops of dil. HCl and filtered.  The filtrate was treated with 
various reagents as shown for the presence of alkaloids.
Mayer’s reagent         -   Creamy precipitate 
Dragandroff’s reagent        -   Orange brown precipitate 
Hager’s reagent          -    Yellow precipitate 
Wagner’s reagent          -     Reddish brown precipitate
4.2.5 Tests for phytosterol
The extract was refluxed with solution of alcoholic potassium hydroxide till 
complete saponification takes place. The mixture was diluted and extracted with 
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ether. The ether layer was evaporated and the residue was tested for the presence of 
phytosterol.
Libermann Burchard Test
The  residue  was  dissolved  in  few  drops  of  acetic  acid,  3  drops  of  acetic
anhydride was added followed by few drops of con. H2SO4.  Appearance of bluish
green colour shows the presence of phytosterol.
4.2.6 Tests for fixed oils
Spot test
Small  quantity  of  extract  was  separately  pressed  between  two  filter  papers.
Appearance of oil stain on the paper indicates the presence of fixed oil. Few drops
of 0.5N alcoholic potassium hydroxide were added to a small quantity of extract
along with a drop of phenolphthalein.  The mixture was heated on water bath for 1-2
hours. Formation of soap or partial neutralization of alkali indicates the presence of
fixed oils and fats.
      4.2.7 Tests for gums and mucilages
Small quantity of the extract was added separately to 25 ml of absolute alcohol
with constant stirring and filtered. The precipitate was dried in air and examined for
its swelling properties for the presence of gums and mucilages.
4.2.8 Tests for Saponins
The extract was diluted with 20 ml of distilled water and it was agitated in a 
graduated cylinder for 15 minutes.  The formation of 1cm layer of foam shows the 
presence of saponins.
4.2.9 Tests for proteins and free amino acids
Small quantity of the extract was dissolved in few ml of water and treated with
following reagents.
A. Millon’s reage Appearance of red colour shows the presence of protein   and
free amino acids.
B.   Ninhydrin  reagent  -  Appearance  of  purple  color  shows  the  presence  of
proteins and free amino acids.
C.  Biuret test - Equal volumes of 5% NaOH solution and 1% copper sulphate
solution were added. Appearance of pink or purple colour shows the presence of
proteins and free amino acids.
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4.2.10 Tests for phenolic compounds and tannins
Small quantity of the extract was taken separately in water and tested for the
presence of phenolic compounds and tannins using following reagents.
A. Dil.FeCl3 solution (5%)                                                   -violet colour
B. 1% solution of gelatin containing 10% NaCl               - white precipitate
C. 10% lead acetate solution                                                   - white precipitate.
4.2.11 Tests for flavonoids
A. With aqueous Sodium hydroxide solution:
Blue to violet colour (anthocyanins), yellow colour (flavones), yellow to orange 
(flavonones)
B. With Con. H2SO4:
Yellow orange colour (anthocyanins), yellow toorange colour (flavones), orange
to crimson (flavonones)
C. Shinoda’s test
Small quantity of the extract was dissolved in alcohol and to that a piece of 
magnesium followed by Con. HCl drop wise was added and heated.  Appearance of 
magenta colour shows the presence of flavonoids.
The results of preliminary phytochemical studies of the  plant root extract are 
presented in Table 1.
Phytoconstituents Presence or Absence
AbsentCarbohydrates +
Glycosides +
Fixed oils and fats -
Gums & mucilage -
Potein & amino acids -
Saponins +
Tannins +
Phytosterols +
Flavonoids +
Alkaloids +
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Steroids +
                         Presence: +, Absence:-
Selection of Dose: In the present study we have selected three doses i.e. 200 mg/kg 
and 400 mg/kg of body weight, selection of doses is based upon toxicity study. In 
the toxicity studies up to 2000 mg/kg body weight animals have not shown any 
signs of toxicity, morbidity and mortality so 10% of the maximum dose have been 
chosen i.e 200 mg/kg body weight, other two doses were selected one is submax 
and other is supramax of 200 mg/kg body weight.
Preparation of the drug solution
Metformin:  Solution  was  prepared  by  dissolving  Metformin  (Alembic)  in
distilled water. The drug was prepared daily and was stored at room temperature
away from sunlight  and moisture.  The volume of  drug solution were calculated
based upon the body weight of the animal
Experimental induction of Diabetic in rats54
 After  a  48 hr  fast,  the  animals  was  given intraperitoneal  (i.p)  injections  of
alloxan  monohydrate  (150mg/kg)  dissolved  in  0.9%  sodium  chloride.  Control
animals received i.p injections of 0.9% sodium chloride. Within 48 hrs following
alloxan  administration,  blood  glucose  concentration  were  estimated  by (Glucose
check monitoring system) diagnostic kit (Apex). The rat with serum glucose levels
more  than 250mg/dl  were  selected  for  the  present  study.  After  the  induction  of
diabetes in the animals diabetic rats were randomly selected into five groups of 6
animals each. ie. Normal, control 0, (diabetic untreated) and diabetic animals treated
with Metformin (10mg/kg,O.D) with AECR (200mg/kg, O.D)  AECR (400mg/kg,
O.D) treated. Treatment begin from the day of blood sugar levels (BSL) detection
after  the alloxan treatment.  Body weight  was recorded daily and serum glucose
level measured on 1st, 7th, 14th  day of study.
Animal Groupings
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ESTIMATION OF NOCICEPTION
Tail immersion (Hot water) test: 
Tail of rat was immersed in a hot water bath (52.5 ± 0.5 °C) until tail withdrawal
(flicking response) or signs of struggle were observed (cut-off 12 s). Shortening of
the  tail  withdrawal  time  indicates  hyperalgesia55,56  (Kannan  et  al.,  1996;
Ramabadran et al., 1989).
 Hot plate test
The  hyperalgesic  response  on  the  hot-plate  is  considered  to  result  from  a
combination of central and peripheral mechanisms55 (Kannan  et al., 1996). In this
test, animals were individually placed on a hot-plate (Eddy’s Hot-Plate) with the
temperature adjusted to 55 ± 1 °C. The latency to the first sign of paw licking or
jump response to avoid the heat was taken as an index of the pain threshold; the cut-
off time was 10 s in order to avoid damage to the paw.
Assessment of Cold allodynia
Rationale 
Allodynia is hallmark of neuropathic pain, and diabetic neuropathy pain in 
experimental animals.
Procedure 
The method was performed as described earlier57,58 (Kumar et al., 2011; Naik et
al., 2006). In brief, 2 h after assessment of thermal hyperalgesia cold allodynia was
assessed by measuring paw (ipsilateral) withdrawal latency (PWL). Ice cold water
(4±10C) was taken in beaker. The paw of rat was submerged gently in water and the
withdrawal time was measured on 1, 7th, 14th day after chronic constriction injury
and in the case of diabetic neuropathy it was assessed weekly after confirmation of
diabetes. A cut off 20 sec was maintained throughout the experiment.
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EVALUATION OF BLOOD GLUCOSE LEVELS AND BODY WEIGHT
Blood glucose levels were measured with a portable glucometer (CONTOUR
TS). In brief, blood was withdrawn from the rats using tail vein rupture method, and
a drop of blood was placed on the glucometer strip loaded in the glucometer for
blood glucose determination. During the experiment, blood glucose levels and body
weights were verified in the interim of each week.
BIOCHEMICAL ESTIMATION
On day 14, blood was collected by retrobital punture under mild ether anesthesia
from overnight  fasted rats and fasting blood sugar59  (Giordano et  al.,  1989) was
estimated.  Serum  was  separated  and  analyzed  for  serum  creatinine60 (Bowers,
1980),  serum  urea61 (Wilson,  1966),  serum  uric  acid,  SGOT  and  SGPT  were
estimated.
Serum Creatinine (Mod. Jaffe’s kinetic method)62
Principle 
Picric acid in alkaline medium reacts with creatinine to form a orange coloured
complex with the alkaline picrate. Intensity of colour formed during the fixed time
measured at 520 nm is directly proportional to the amount of creatinine present in
sample.
Creatinine + alkaline picrate                         Creatinine picrate complex
Pipette in to test 
tubes
Standard Sample
Working reagent 1000 µl 1000µl
Standard 100 µl ……..
Sample ……… 100 µl
               Mix and read the variation of absorbance (∆A) between 30 seconds and 90 seconds
Calculation :
With standard or calibrator
Concentration in sample (mg/dl) =   Concentration of Standard   X  ∆ A Sample 
                                                                  ∆ A Standard
Uric acid63
Principle:
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Uric acid is oxidized to allantoin by uricase. The generated hydrogen peroxide 
reacts with 4-aminoantipyrine and DHPS to quinoneimine. 
                                         Uricase
Uric acid + H2O + O2                         Allantoin + CO2 + H2O2
DHPS + 4-Aminoantipyrine + 2 H2O2                   Quinoneimine + 3 H2O
   
Assay procedure
Pipette in to test tubes Blank Standard Sample
Working reagent 1 1000 µl 1000 µl 1000µl
Distill water 25µl ……… ……..
Standard ……… 25 µl ……..
Sample ………. ……… 25 µl
Mix and read the absorbance (A) after a 10 minutes incubation but within 30 
minutes.
Calculation : 
With standard or calibrator
                                             Concentration of Standard
Conc. of unknown Sample =                                       x
                             Abs. Standard - Abs. of Reagent Blank
Urea64
Principle
Enzymatic determination according to the following reactions : 
                               Urease
Urea + 2H O                         2NH4++ Co3-2 
                                               GLDH
 NH4+ +Tris Base + NADH                         L-Glu+NAD+ + H2O
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Abs. of unknown 
Sample – Abs.of 
Reagent Blank
     
ASSAY PROCEDURE: Two Reagent Procedure 
Standard Sample / 
Control
R1 800 µl 800 µl
R2 200 µl 200 µl
Mix and Incubate at 37°C for 2 minutes then add
Pipette in to test tubes Standard Sample
Working reagent 1000 µl 1000µl
Standard 10µl ……..
Sample ……… 10µl
Mix and read the variation of absorbance (∆A) between 30 seconds and 60 
seconds.
CALCULATION:
With standard or calibrator
                                                  
                                                         Concentration of Standard
Concentration in Sample (mg/dl) =                                            X ∆ A Sample
                                                                ∆ A Standard
SGOT/AST65
Principle 
Kinetic determination of the aspartate aminotransferase (GOT) activity: 
                                                                
                                                              GOT
L - Aspartate + α – Ketoglutarate                             Oxaloacetate + L-Glutamate
                                                         MDH
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Pipette in to test tubes Sample/Control
R1 800µl
R2 200 µl
Mix and Incubate at 37°C for 2 minutes then add
Pipette in to test tubes Sample/Control
Working reagent 1000µl
Sample/Control 100 µl
Mix and after a 60 seconds incubation at 37°C measure the change of 
absorbance per 
minute (∆A/minute) during 180 seconds.
Calculation :
Activity of Sample (U/L) = ∆ A/Min X 1746
SGPT/ ALT66
Principle 
Kinetic determination of the GPT activity
                                                            GPT
L - Alanine + α – Ketoglutarate                                   Pyruvate + L-Glutamate
                                                 LDH
Pyruvate + NADH + H+                                L-Lactate + NAD+
ASSAY PROCEDURE 1:  Two Reagent procedure
Pipette in to test tubes Sample/Control
R1 800µl
R2 200 µl
Mix and Incubate at 37°C for 2 minutes then add
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Pipette in to test tubes Sample/Control
Working reagent 1000µl
Sample/Control 100 µl
Mix and after a 60 seconds incubation at 37°C measure the change of 
absorbance per 
minute (∆A/minute) during 180 seconds.
Calculation :
Activity of Sample (U/L) = ∆ A/Min X 1746
Histopathological studies:
At the end of the study period, animals from all the five groups were sacrificed
and pancrease was dissected out, washed, 5µm thick section slides were prepared
and stain with heamatoxyline-eosin and examined by light microscopy.
STATISTICAL ANALYSIS 
Results  were  expressed as  mean±SEM. The data  were analyzed by one-way
analysis of variance (ANOVA) followed by Dunnett’s multiple comparison tests.
Statistical significance was considered at P<0.05 in all the cases.
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   RESULTS 
Acute toxicity study
The overall study showed the LD50 of oral toxicity of extracts AECR to be 
above 2000 mg/kg b.w. in mice. So, the extracts are safe for long term 
administration.
Preliminary phytochemistry of the plant extract 
The yield of aqueous extract of  Cyperus rotundus  root was found to be 7.9 %
W/W. Preliminary phytochemical analysis revealed that the plant possessed phyto
constituents  alkaloids,  steroids,  saponins,  tannins,  Phytosterols,  flavonoids,
glycosides and carbohydrates.
Effect of AECR on blood sugar level (BSL) in alloxan induced diabetes in
rats.
The effect of repeated oral administration of aqueous extract of AECR on blood
glucose levels in alloxan-diabetic rats is presented in table-1, and the effect on body
weight is presented in table-2.  In an alloxan diabetic rats serum glucose level has
significantly  increased  (p<0.001)  in  diabetic  control  (289.65±3.071) rats  when
compared to normal groups (87.76±2.056).
AECR, administered at doses of 200 (87.45±1.987) & 400 (80.55±1.998) mg/kg
to alloxan-treated diabetic rats caused significant (p<0.01) and (p<0.001) reduction
of blood glucose levels which was related to dose and duration of treatment as when
compared  to  control  diabetic  group  (289.65±3.071).  Maximum  reduction  was
observed on day 14. gradual increase in body weight was also observed. AECR 200
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and  400mg/kg  exhibited  maximum  glucose  lowering  effect  in  diabetic  rats.
Administration  of  Metformin  14.25  mg/kg  (82.49±2.421)  orally  for  14  days
Table.1: Effect of AECR on blood sugar level (BSL) in alloxan induced diabetes
in rats.
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Treated groups
Serum blood glucose level
Groups 0-DAY
 
1st-DAY 7th-DAY 14th-DAY
Normal 92.00±3.540 92.839±2.030 87.44±2.162 87.76±2.056 
Control (Alloxan 120mg/kg) 243.00±7.739 248.68±6.89 275.57±4.986b 289.65±3.071a 
Standard (Metformin 
14.25mg/kg) 
229.83±5.597 160.35±2.81 102.54±3.789** 82.49±2.421***
AECR 200 mg/kg 240.00±3.765 190.12±2.055 109.10±3.312* 87.45±1.987** 
AECR 400 mg/kg 251.68±6.332 194.15±2.345 96.90±1.54** 80.55±1.998***
     
             Data expressed in Mean ± S.E.M. n=6, ANOVA followed by Dunnett’s 
multiple comparison test *p<0.05, **p<0.01, ***p<0.001 as    compared to Control 
group.and ap<0.001, bp<0.01 as compared to Normal group.
Fig.no1: Effect of AECR on blood sugar level (BSL) in alloxan induced 
diabetes in rats
Serum blood glucose level
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Data expressed in Mean ± S.E.M. n=6, ANOVA followed by Dunnett’s multiple 
comparison test *p<0.05, **p<0.01, ***p<0.001 as compared to Control group.and 
ap<0.001 as compared to Normal group.
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Effect of AECR on allodynia produced by tail immersion (cold water) in 
alloxan induced diabetes in rats.
Rats treated with alloxan (8.978±1.080) had significant (p<0.01) decrease in tail
flick latency was observed after 14 days of diabetic complication induction in cold
immersion test as compared normal group (12.53±0.588). This deficit in tail flick
response latency was significantly (p<0.001) reversed on 14 days treatment with
AECR 200 and 400mg/kg).
Administration  of  Metformin  14.25  mg/kg  (13.77±0.48)  orally  for  14  days
treatment were reduced significantly tail  flick latency (p<0.001)  as  compared to
control groups (12.53±0.588).
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                   Table.2: Effect of AECR on allodynia produced by tail immersion (cold water) in alloxan induced diabetes in rats.
Data expressed in Mean ± S.E.M. n=6, ns= not significant, ANOVA followed by Dunnett’s multiple comparison test **P<0.01***p 
<0.001 as compared Control group. and ap<0.001 and bp<0.01 as compared Normal group.
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Treatment Groups
Tail Flick latency in seconds
Day-1 Day-7 Day-14 
Normal 11.23±0.971 5.252±0.537 12.53±0.588 
Control (Alloxan 120mg/kg) 7.57±0.649b 2.842±0.449a 8.978±1.080b 
Standard (Metformin 
14.25mg/kg)
12.45±0.799*** 4.972±0.311** 13.77±0.480*** 
AECR 200 mg/kg 8.45±0.780ns 4.84±0.189** 13.68±0.510*** 
AECR 400 mg/kg 8.475±0.548ns 5.123±0.273*** 13.92±0.419*** 
     
Fig.no.2:Effect of AECR on allodynia produced by tail immersion (cold 
water) in alloxan induced diabetes in rats.
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Data expressed in Mean ± S.E.M. n=6, ns= not significant, ANOVA followed by
Dunnett’s multiple comparison test *p<0.05, **p<0.01, ***p<0.001 as compared to 
Control group.and bp<0.01 and cp<0.05 as compared to Normal group.
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Effect of AECR on hyperalgesia produced by tail immersion (hot water) in 
alloxan induced diabetes in rats.
There was no change in tail flick latency (sec) observed in normal group of
animals throughout the experiment. A gradual decline in the latency was observed in
control  group of animals from day 7th (6.333±0.49 p<0.05) onwards which was
observed minimum on day 14th (4.785±0.594, p<0.01), indicating the presence of
neuropathic pain due to diabetes. 
AECR 200, 400mg/kg and Metformin 14.25mg/kg group of animlas recorded a
reduction in latency on day 14th (p<0.001) which was followed by increase in pain
threshold time on subsequent days, indicating absence of algesia produced by tail
immersion in hot water.
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Table: no.3: Effect of AECR on allodynia produced by tail immersion (hot water) in alloxan induced diabetes in rats.
Treatment group Tail Flick Latency in seconds (hot water)
Day-1 Day-7 Day-14
Normal 6.233±0.357 10.83±0.909 10.35±0.986 
Control (Alloxan 120mg/kg) 3.935±0.220b 6.333±0.494c 4.785±0.594b 
Standard (Metformin 
14.25mg/kg)
6.720±0.240** 10.50±0.885** 9.508±0.840*** 
AECR 200 mg/kg 5.680±0.7733ns 9.333±0.802* 6.730±0.683*** 
AECR 400 mg/kg 6.583±0.560** 12.67±0.802* 9.535±0.320*** 
 Data expressed in Mean ± S.E.M. n=6, ns= not significant, ANOVA followed by Dunnett’s multiple comparison test* p<0.05, **p<0.01, 
***p <0.001 as compared to Control group. and bp<0.01 and cp<0.05 as compared to Normal group.
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Fig. 3: Effect of AECR on allodynia produced by tail immersion (hot water)
in alloxan induced diabetes in rats.
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Data expressed in Mean ± S.E.M. n=6, ns= not significant, ANOVA followed by
Dunnett’s multiple comparison test* p<0.05, **p<0.01, ***p <0.001 as compared to
Control group. and bp<0.01 and cp<0.05 as compared to Normal group.
Effect of AECR on thermal hyperalgesia (hot plate) in alloxan induced diabetes
in rats.
The nociceptive threshold was significantly lower (p<0.05) in diabetic rats as
compared with the normal group. For Control group of animals there was a gradual
reduction in latency (sec) observed from day 7th (2.33±0.21, p<0.05) to till day 14th
(3.067±0.29 p<0.001) where the pain was observed to be maximum, indicating the
presence of algesia by heat. In the drug treated group of animals,  no significant
lowering in pain latency was exhibited which implies the protective action of AECR
on hyperalgesia produced in diabetic animals.
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   Table.no.4: Effect of AECR on thermal hyperalgesia (hot plate) in alloxan induced diabetes in rats.
  Treatment group    Thermal Hyperalgesia Latency in sec
Licking Jumping
Day-1 Day-7 Day-14 Day-1 Day-7 Day-14
Normal 8.50±0.76 7.00±0.93 6.33±1.22 4.76±0.39 7.00±o.68 5.74±0.36
Control (Alloxan 
120mg/kg)
3.96±0.53 3.33±0.33c 2.33±0.84c 3.50±0.22 c 2.33±0.21b 3.067±0.29a
Standard 
(Metformin 
14.25mg/kg)
7.83±0.79ns 7.66±1.11** 6.33±1.11* * 4.85±0.17* 7.50±0.42* 4.85±0.17**
AECR 200 mg/kg 9.50±0.76ns 6.16±0.70* 8.33±0.49** 5.33±0.24* 7.00±0.68* 5.33±0.24***
AECR 400 mg/kg 4.50±0.76** 8.33±0.66* 9.66±1.11*** 7.66±0.49** 7.50±2.47* 7.66±0.49***
Data expressed in Mean ± S.E.M. n=6, ns= not significant, ANOVA followed by Dunnett’s multiple comparison test *p<0.05, **p<0.01, 
***p<0.001 as compared to Control group. and ***p<0.001, cp<0.05 as compared to Normal group.
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Fig.4: Effect of AECR on thermal hyperalgesia (hot plate)paw licking and 
jumping in alloxan induced diabetes in rats.
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Data expressed in Mean ± S.E.M. One way  ANOVA followed by Dunnett’s 
multiple comparison test *p<0.05, **p<0.01, as compared to Control group. and 
ap<0.001,bp<0.01, cp<0.05 as compared to Normal group
Thermal hyperalgesia (Jumping)
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Data expressed in Mean ± S.E.M. One way ANOVA followed by Dunnett’s multiple
comparison test *p<0.05, **p<0.01,***p<0.001 as compared to Control group. and 
ap<0.001, cp<0.05 as compared to Normal group.
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Effect  of  AECR  on  Serum  biochemical  parameters  in  alloxan  induced
diabetes in rats
Urea
The results for the effect  of the AECR in the mean values of serum urea on
normal  and  (51.89±0.05)  diabetic  rats  are  presented  in  Table  no  4.  Our  data
indicated  that  there  were  the  mean values  of  urea,  (p<0.001) were  significantly
higher in control rats as compared to the normal rats (20.53±0.07). Administration
of Metformin 14.25mg/kg had exhibited significantly (26.92±0.21) (p<0.01) lower
serum urea as compared to diabetic control group (51.89±0.05).Treatment of the
diabetic rats with the AECR extract 200 (34.48±0.05) & 400 mg/kg (25.64±0.04)
for 14 days caused a significant decrease in urea (p<0.05, p<0.01), as compared to
control group (51.89±0.05).
Creatinine
The data indicated that there were the mean values of creatinine (p<0.001) were
significantly  higher  in  control  rats  (0.88±0.02)  as  compared  to  the  normal  rats
(0.46±0.01). Administration of Metformin 14.25mg/kg had exhibited significantly
(0.47±0.02) (p<0.001) lower serum creatinine as compared to diabetic control group
(0.88±0.02).Treatment of the diabetic rats with the AECR extract 200 (0.67±0.02) &
400  mg/kg  (0.51±0.01)  for  14  days  caused  a  significant  decrease  in  creatinine
(p<0.01, p<0.001), as compared to control group (0.88±0.02).
Uric aicd
The data indicated that there were the mean values of uric acid (p<0.001) were
significantly  higher  in  control  rats  (4.74±0.06)  as  compared  to  the  normal  rats
(3.76±0.06). Administration of Metformin 14.25mg/kg had exhibited significantly
(1.64±0.05) (p<0.001) lower serum uric acid as compared to diabetic control group
(4.74±0.06).Treatment of the diabetic rats with the AECR extract 200 (1.65±0.03) &
400  mg/kg  (2.31±0.06)  for  14  days  caused  a  significant  decrease  in  uric  acid
(p<0.001, p<0.01), as compared to control group (4.74±0.06).
SGOT
The data indicated that there were the mean values of SGOT (p<0.001) were
significantly higher  in  control  rats  (45.36±2.23)  as  compared to  the normal  rats
(37.31±0.88). Administration of Metformin 14.25mg/kg had exhibited significantly
(39.46±0.60) (p<0.01) lower serum SGOT as compared to diabetic control group
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(45.36±2.23).  Treatment  of  the  diabetic  rats  with  the  AECR  extract  200
(40.65±0.68) & 400 mg/kg (34.00±0.80) for 14 days caused a significant decrease
in SGOT (p<0.05, p<0.001), as compared to control group (45.36±2.23).
SGPT
The data indicated that there were the mean values of SGPT (p<0.001) were
significantly higher  in  control  rats  (77.90±6.07)  as  compared to  the normal  rats
(51.35±0.96). Administration of Metformin 14.25mg/kg had exhibited significantly
(50.48±0.62) (p<0.001) lower serum SGPT as compared to diabetic control group
(77.90±6.07).  Treatment  of  the  diabetic  rats  with  the  AECR  extract  200
(54.23±1.31) & 400 mg/kg (62.25±0.90) for 14 days caused a significant decrease
in SGPT (p<0.001, p<0.01), as compared to control group (77.90±6.07). 
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Table.no:5:  Effect  of  AECR  on  Serum  biochemical  parameters  in  alloxan
induced diabetes in rats
Data expressed in Mean ± S.E.M. n=6, ANOVA followed by Dunnett’s multiple 
comparison test,*p<0.05, **p<0.01,***p<0.001 as compared to Control group.and 
ap<0.001 as compared to Normal group.
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SERUM BIOCHEMICAL PARAMETERS
Testing group UREA mg/dl CREATININE 
mg/dl 
URIC ACID 
mg/dl 
SGOT  mg/dl SGPT  
mg/dl
Normal 20.53±0.07 0.46±0.01 3.76±0.06 37.31±0.88 51.35±0.96
Control (Alloxan 
120mg/kg)
51.89±0.05a 0.88±0.02a 4.74±0.06a 45.36±2.23a 77.90±6.07a
Standard 
(Metformin 
14.25mg/kg) 
26.92±0.21** 0.47±0.02*** 1.64±0.05*** 39.46±0.60** 50.48±0.62*
**
AECR 200 mg/kg 34.48±0.05* 0.67±0.02** 1.65±0.03*** 40.65±0.68* 54.23±1.31*
**
AECR 400 mg/kg 25.64±0.04** 0.51±0.01*** 2.31±0.06** 34.00±0.80*** 62.25±0.90*
*
     
Fig.5:Effect of AECR on Serum urea in alloxan induced diabetes in rats.
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Data expressed in Mean ± S.E.M. One way ANOVA followed by Dunnett’s multiple 
comparison test *p<0.05, **p<0.01 as compared to Control group. and ap<0.001 as 
compared to Normal group.
Fig.6: Effect of AECR on Serum creatinine in alloxan induced diabetes in rats.
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Data expressed in Mean ± S.E.M. One way ANOVA followed by Dunnett’s multiple 
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comparison test **p<0.01,***p<0.001 as compared to Control group. and ap<0.001 as 
compared to Normal group.
Fig.7: Effect of AECR on Serum uric acid in alloxan induced diabetes in rats.
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Data expressed in Mean ± S.E.M. One way ANOVA followed by Dunnett’s multiple 
comparison test **p<0.01,***p<0.001 as compared to Control group. and ap<0.001 as 
compared to Normal group.
Fig.8: Effect of AECR on Serum SGOT in alloxan induced diabetes in rats.
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Data expressed in Mean ± S.E.M. One way ANOVA followed by Dunnett’s multiple 
comparison test *p<0.05, **p<0.01 as compared to Control group. and ap<0.001 as 
compared to Normal group.
Fig.9: Effect of AECR on Serum SGPT in alloxan induced diabetes in rats.
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Data expressed in Mean ± S.E.M. One way ANOVA followed by Dunnett’s multiple 
comparison test **p<0.01,***p<0.001 as compared to Control group. and ap<0.001 as 
compared to Normal group.
Histopathology of Pancrease
The histopathological changes were observed in control and experimental group rats.
The control rat’s pancreas showed that the normal appearance of islet cells. The alloxan
treated rats showed vacuolization, necrotic changes and reduced islet cells of pancreas
damage were observed. Oral administration of aqueous extract of Cyperus rotundus at the
dose of 200 and 400 mg/kg body weight to alloxan treated rats showed markedly reduced
the extent of necrosis, vacuolization and reduced islet cells of pancreas. In the reference
group, i.e., alloxan with metformin, pancreas architecture was similar to that observed in
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the  control  rats.  The  maximum  curative  effect  against  alloxan  induced  diabetic
aberrations was achieved with the 400 mg/kg body weight.
Fig. Microphotographs of pancreas tissue examined by routine hematoxylin-eosin of
alloxan treated animals.  A: Normal group, B: Control group (alloxan 120mg/kg), C:
Metformin 14.25mg/kg, D: AECR 200mg/kg, E: AECR 400mg/kg.
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  VII.DISCUSSION
The acute toxicity test of AECR in mice produced no death or signs of toxicity even at
the dose of 2000 mg/kg which shows that the extract was well tolerated and the test doses
safe in the animals.
The antidiabetic activity of AECR was evaluated in alloxan-induced diabetic rats by
testing its effect on fasting blood glucose level using auto analyzer (Accu Check Active®)
glucose kit. The fasting blood sugar test is a carbohydrate metabolic test which measures
plasma or blood glucose levels after a fast  (usually 8–12 h).  During fasting the body
stimulates the release of the hormone glucagon, which in turn releases glucose into the
blood through catabolic processes. Normally, the body produces and processes insulin to
counteract the rise in glucose levels but in diabetes, this process does not occur and tested
glucose levels normally remain high63. Alloxan is one of the usual substances used for
induction of diabetes mellitus apart from streptozotocin and has a destructive effect on the
beta (β) cells of the pancreas as previously reported by64.  Pancreas is the primary organ
involved in sensing the organism’s dietary and energetic states via glucose concentration
in the blood and in response to elevated blood glucose, insulin is secreted65. However,
alloxan causes diabetes through its ability to destroy the insulin-producing-cells of the
pancreas66. When there are not enough available beta-cells to supply sufficient insulin to
meet the needs of the body, insulin-dependent diabetes results67
A  strong  relationship  involves  between  glycemia  and  diabetic  micro  vascular
complications  in  both  type  1  and  type  2  diabetes   production  of  superoxide  due  to
oxidative stress in  diabetes  may be cause  for  vascular  and neuronal  complications of
painful  neuropathy 68. In  diabetes,  intracellular  hyperglycemia  causes  abnormalities  in
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blood flow and increased vascular permeability. Quantative and qualitative abnormalities
of extracellular matrix contribute to an irreversible increase invascular permeability. With
microvascular  cell  loss  occurs  in  part  as  a  result  of  programmed  cell  death.
Hyperglycemia  may  also  decrease  production  of  trophic  factors  for  endothelial  and
neuronal cells. Together, these changes lead to odema, ischaemia and hypoxia induced
neovascularization  in  the  retina,  proteinurea,  messengial  matrix  expansion,
glomerulosclerosis  in  the  kidney  and  multifocal  axonal  degeneration  in  peripheral
nerves69. Impaired  blood  flow  also  seems  to  contribute  to  noxious  stimulus
hypersensitivity. Oxidative stress related reduction in perfusion is thought to play a part in
cardiac autonomic dysfunction and also in small fiber sensory neuropathy70.  Alloxan and
the products  of  its  reduction,  dialuric  acid,  establish a  redox cycle with formation of
superoxide radicals. These radicals undergo dismutation to hydrogen peroxide. Thereafter
highly  reactive  hydroxyl  radicals  are  formed  by  the  Fenton  reaction.  The  action  of
reactive oxidant species (ROS) with a simultaneous massive increase in cytosolic calcium
concentration  cause  rapid  Beta  cell  destruction71. Early  pharmaceutical  intervention
against the long-term consequences of hyperglycemia induced cross-linking prevents the
development of severe late complications of diabetes. 
Hyperglycemia has  also been recently implicated in initiation and development  of
various  types  of  diabetic  complications.  Nephropathy  is  one  of  these  serious  micro
vascular complications that has been observed in diabetic individuals72. In addition, blood
urea, uric acid and creatinine concentrations were increased among uncontrolled diabetic
individuals  and  this  increase  could  be  a  result  of  impaired  renal  function  due  to  an
increased blood glucose level. Our results revealed for the first time that the mean values
of  these  end  products  in  the  serum  increased  in  untreated  diabetic  rats,  while  they
significantly  decreased  after  the  administration  of  AECR.  Thus,  this  extract  might
improve renal function which, in turn, leads to reduction in these end products. It  was
reported that diabetic individuals had lower serum creatinine concentrations as well as
higher  serum  uric  acid  and  urea  levels  than  nondiabetic  individuals  73,74.  Thus,  the
reduction in urea and creatinine levels probably can be explained by a reduction in blood
glucose level.
Moreover, high levels of serum uric acid, urea and creatine and SGOT and SGPT may
act as a marker of kidney and liver problems. Thus, it  is possible to suggest that this
extract might play an important role in reducing risk of kidney and liver problems as well
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as neuroprotective by lowering  both hyperalgesia and allodynia as well as  serum urea,
uric acid, creatinine SGOT and SGPT The hyperalgesic response in tail-withdrawal test is
generally attributed to central mechanisms whereas the hyperalgesic response on hot plate
is  attributed  to  the  combination  of  both  central  and  peripheral  mechanisms  75,76.  The
beneficial effects that have been seen for the first time in our study are indications of
safety of AECR extract. 
Chapter: VIII
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                                                                   Conclusion
                                        VIII. CONCLUSION
 The  conclusion,  reveals  that  oral  administration  of  aqueous  extract  of  cyperus
rotundus.  exhibit, Neuroprotective, nephroprotective and hepatoprotective activities via
enhancing  insulin  production  and  decreasing  glucogan  production  and  decreasing  a
SGOT snd SGPT level in alloxan induced diabetic rats. Thus, oral  use of this extract
might positively affect the functional capacities of various rat tissues, particularly blood,
kidney , liver and nerves against toxic action of alloxan compound (dose of 150 mg/Kg
bw). These findings clearly support the traditional use of this medicinal plant in treatment
of diabetes mellitus and complications shed more light in the efficacy of this plant. Thus,
Cyperus rotundus appears to a valuable plant and ideally suited to be used in treatment of
DM and prevent or delay the onset of its complications in humans, since this is a non-
toxic plant.
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• Diabetes is a group of metabolic disorder of carbohydrate, fat, and protein metabolism
resulted from destruction of insulin secreting pancreatic beta-cells, defects in insulin
production, insulin action, or both, characterized by hyperglycemia.
• The chronic  hyperglycemia results  in  long-term complications  of  diabetes  include
peripheral neuropathy, nephropathy and hepatic damage .
• In  this  study  the  plant  root  Cyperus  rotundus had  selected  for  the  evaluation  of
diabetic complication. This  plant  has been claimed to cure nervine tonic,  diuretic,
antiperiodic, and traditionally used to treat diarrhoea, dysentery, leprosy, bronchitis,
amenorohoea, dysmenorrhoea, renal and vesical calculi, ophthalmic disorders, blood
disorders and general debility.
• Preliminary  phytochemical  analysis  revealed  that  the  plant  root  possessed  phyto
constituents alkaloids, steroids, saponins, tannins, Phytosterols, flavonoids, glycosides
and carbohydrates.
• Type  II  diabetic  mellitus  was  induced  in  male  wistar  albino  rats  body weight  of
animals 180-220 selected for the study.
• Evaluation  of  diabetic  complications  activity  was  assessed  by  using  alloxan
experimental model by administration of alloxan 120mg/kg i.p. for 14 days.
• Body weight and serum blood glucose were recorded before administration of AECR
and metformin to the animals.
• Selected animals were then administered the alloxan 120mg/kg significantly increased
the blood glucose levels in all animals.
• Administration of AECR and standard metformin were significantly reduced elevated
level of serum glucose level.
• Animals treated with alloxan had significant decreased in tail immersion (cold water
test) tail flick latency was observed after 14 days of diabetic complication induction in
cold immersion test as compared normal group.
• AECR  200,  400mg/kg  and  Metformin  14.25mg/kg  group  of  animlas  recorded  a
reduction in latency on day 14th which was followed by increase in pain threshold
time on subsequent days, indicating absence of algesia produced by tail immersion in
hot water.
• Diabetic  control  rats  had  exhibited  the  elevated  serum urea,  creatinine,  uric  acid
SGOT and SGPT liver enzyme.
• Animals were sacrificed after 14 days and blood was withdrawn from retro-orbital
puncture  for  various  biochemical  estimations  and  pancreas  collected  for
histopathological study
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• Administration  of  AECR  200,  400  mg/kg  and  Metformin  14.25mg/kg  had
significantly decreased the elevated level of biochemical markers such as serum urea,
uric acid, creatinine SGOT, and SGPT as compared to diabetic control rats.
. Page 91
     
                    
References
. Page 92
     
                                       REFERENCES
1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of
the  Expert  Committee  on  the  Diagnosis  and  Classification  of  Diabetes  Mellitus.
Diabetes Care 1997;20:1183–1197.
2. Johnson  D,  Palumbo  P,  Chu  C:  Diabetic  ketoacidosis  in  a  community-based
population. Mayo Clinic Proc 55:85-88, 1980.
3. Wild  S,  Roglic  G,  Green  A,  Sicree  R,  King  H.  Global  prevalence  of  diabetes:
Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27 : 1047-
53. 
4. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D,
editor.  Diabetes  Atlas.International  Diabetes  Federation.  3rd  ed.  Belgium:
International Diabetes Federation; 2006 p. 15-103. 
5. Hongmei  Chen,  Sachin  Brahmbhatt,  Akanksha  Gupta  and  Avadhesh  C
Sharma*Duration  of  streptozotocin-induced  diabetes  differentially  affects  p38-
mitogen-activated  protein  kinase  (MAPK)  phosphorylation  in  renal  and  vascular
dysfunction Cardiovascular diabetology 2005 jul; 4(3):1-18 
6. World  Health  Organization.  Defination,  diagnosis  and  classification  of  diabetes
mellitus and its complications-Report of a WHO Conclusion. Geneva: World Health
Organisation; 1999;2 
7. Oki JC, Isley L. Diabetes mellitus. In: Dipro JT, Tablbert Rl, Yee GC, Matzke GR,
Wells  BG, Posey LM editors.  Pharmacotherapy:  A pathophysilogica approach.  5th
international ed, New York: Mc Graw Hill Medical publishing division 2002; 1335-
56.
8. Satyanarayana  T,  Katyayani  BM,  Hemalatha  E,  Anjana  AM,  Chinna  EM.
Hypoglycemic  and  antihyperglycemic  effect  of  alcoholic  extract  of  Euphorbia
leucophylla  and  its  fractions  in  normal  and  in  alloxan  induced  diabetic  rats.
Pharmacog Mag. 2006;2:244–253.
9. West  J.B.  Best  and  Taylor’s  Physiological  Basis  of  medical  practice.  12th  ed
Baltimore, Williams & Wilkins 1990; 754-55 
10. Guyton  AC.  A Text  Book  of  Medical  Physiology.  9th  ed.  London,  W.B.
Saunders Company.1998; 1:971.
11. Tortora  G.T.and  Grabowski  S.R.  Principles  of  anatomy  and  physiology.
8thed .Harper Collins college publishers Inc1996; 533.
. Page 93
     
12. Tortora G.T. and Grabowski S.R. Principles of anatomy and physiology. 8th
ed. Harper Collins college publishers Inc1996; 533.
13. Lamb EJ, Day AP. New diagnostic criteria for diabetes mellitus: are we any
further forward? Ann Clin Biochem 2000; 37: 588-92. 
14. The  expert  committee  on  the  diagnosis  and  classification  of  diabetes
mellitus .Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003
Nov; 26(11): 3160-67.
15. World  Health  Organization.  Definition,  Diagnosis  and  Classification  of
Diabetes Mellitus and its  Complications- Report of a WHO Consultation.  Geneva:
World Health Organization; 1999. p. 9. 
16. Setter SM, White JR, Campbell RK. Diabetes In; Harfindal ET, Gourley DR.
editors.  Textbook  of  therapeutics:  Drug  and  disease  management.  7th  ed.  USA:
Lippincott Williams & wilkins; 2000. p. 377. 
17. Christopher H, Edwin RC, John Hunter AA, Nicholas AB, editors. Davidson’s
Principle and practice of Medicine.17th ed. Edinburgh: ELBS Churchill Livingstone;
1995. p. 725-26. 
18. World Health Organization. Definition, diagnosis and classification of diabetes
mellitus and its complications- Report of a WHO Consultation. Geneva: World Health
Organization; 1999. p. 25-34. 
19. Michael JC, James MC, Vinay K. The pancreas. In: Vinay K, Tucker C, Ramzi
SC  editors.  Robbins,  Pathologic  basis  of  disease.  6th  ed.  Harcourt  publishers
international company; 2000. p. 643-47. 
20. Bach  JF.Insulin-dependent  diabetes  mellitus  as  an  autoimmune  disease.
Endocrinol Rev 1994; 15 (4): 516. 
21. Rothe H,  Jenkins  NA, Copeland  NG,  Kolb H.  Active  stage  of  autoimmne
diabetes is associated with the expression of a novel cytokine, IGIF, which is located
near Idd2. J Clin invest 1997; 99(3): 469-74. 
22. Setter SM, White JR, Campbell RK. Diabetes In; Harfindal ET, Gourley DR.
editors.  Textbook  of  therapeutics:  Drug  and  disease  management.  7th  ed.  USA:
Lippincott Williams & wilkins; 2000. p. 381-84.
23. Virkamaki  A,  Ueki  K,  Kahn  CR.  Protein-protein  interaction  in  insulin
signaling and the molecular mechanism of insulin resistance. J Clin invest 1999 Apr;
103: 931-43. 
. Page 94
     
24. Sacks DB. Amylin- a glucoregulatory hormone involved in the pathogenesis
of diabetes mellitus. Clin Chem 1996; 42(4): 494-495.
25. Patel NS. Evaluation of the antidiabetic activity of a polyherbal formulation
[dissertation].Visveswarapura  Institute  of  Pharmaceutical  Sciences:  Rajiv  Gandhi
University of Health Sciences, Bangalore; 2004 Jul. p. 25-26. 
26. Harsh  Mohan.  Text  book of  pathology.4th ed.  New Delhi:  Jaypee brothers
medical publishers (P) Ltd; 2000. p. 806-08. 
27. Sharma SK. Coma in diabetes mellitus. Type 2 diabetes The Indian scenario.
1st ed. Bangalore: Micro Labs Ltd; 2002. p. 192-00. 
28. Brownlee  M,  Aiello  LP,  Friedman E,  Vinik  AI,  Nesto  RW,  Boulton  AJM.
Complication  of  diabetes  mellitus.  In:  Larsen,  Kronenberg,  Melmed,  Polonsky
editors. William’s textbook of endocrinology. 10th ed. Pennsylvania: Saunders; 2003.
p. 1515-19. 
29. Sherwin RS. Diabetes mellitus. In: Bennett JC, Plum F editors. Cecil textbook
of medicine. 20th ed. Singapore: Harcourt Asia PTE Ltd; 1996. p. 1263-84.
30. Chattopadhyay S, Ramanathan M, Das J, Bhattacharya SK. Animal models in
experimental diabetes mellitus. Indian J Exp Biol 1997 Nov; 35: 1141-5. 
31. Vogel  HG,  Vogel  WH,  editors.  Drug  discovery  and  evaluation-
pharmacological assays. 2nd ed. Germany: Springer-Verlag Berlin Heidelberg; 2002.
p. 947-64. 
32. Szkudelski T. The mechanism of alloxan and Streptozotocin action in β-cells
of the pancreas. Physiol Res 2001; 50: 536-46. 
33. Mansoor SM. Investigation into the antidiabetic effect of brassica oleracea L.
(gongylodes)  [dissertation].Visveswarapura  Institute  of  Pharmaceutical  Sciences:
Rajiv Gandhi University of Health Sciences, Bangalore; 2003 Aug. p. 36-37. 
34. Arulmozhi  DK, Veeranjaneyulu A, Bodhankar SL.  Neonatal  streptozotocin-
induced rat model of type 2 diabetes mellitus: a glance. Indian J Pharmacol 2004 Aug;
36(4): 217-21. 
35. Available  from  URL:  http://www.ars-grin.gov/cgi-bin/npgs/html/taxon.pl?
316644 
36. Zhu  M,  Luk  HH,  Fung  HS,  Luk  CT.  Cytoprotective  effects  of  Cyperus
rotundus against ethanol induced gastric ulceration in rats. Phytother. Res 1997; 11:
392–394. 
. Page 95
     
37. MARTIN,  Robert  &  POL  Chanthy,  2009,  Weeds  of  Upland  Cambodia,
ACIAR Monagraph 141, Canberra, 
38. Holm  et  al.,  LeRoy  G.;  Plucknett,  Donald  L..  (1977).  The  World's  worst
weeds: Distribution and biology. Hawaii: University Press of Hawaii. 
39. Availablfrom
URLhttp://www.hort.purdue.edu/newcrop/cropfactsheets/motha.html .
40. Mitchell C, et al. (translators), Ten Lectures on the Use of Medicinals from the
Personal Experience of Jiao Shude, 2003 Paradigm Publications, Brookline, MA. 
41. Sharma  PC,  Yelne  MB,  Dennis  TJ.  Database  on  medicinal  plants  used  in
Ayurveda.  Delhi:  Documentation  and  Publication  Division,  Central  Council  for
Research in Ayurveda and Siddha. Vol 3. 2001:404-424. 
42. Gupta MB, Palik TK, Sing N, Bhargava KP. Pharmacological studies to isolate
the  active  constituents  from  Cyperus  rotundus possessing  anti-inflammatory,
antipyretic and analgesic activities. Indian J Med Res 1971;59:76-82. 
43. Raut Nishikant A, Gaikwad Naresh J. Antidiabetic activity of hydro-ethanolic
extract of Cyperus rotundus in alloxan induced diabetes in rats. Fitoterapia 2006; 77:
585–588 
44. Majid Nima Zeid abdul, Jabier Majid Sakhi Jabier, Wagi Raghidah Ismaeel,
Kareem Hussain Huda Abd Al. Extraction, Identification and Antibacterial activity of
Cyperus oil from Iraqi C. rotundus, Eng. & Technology 2008; 26: 10. 
45. Nagulendran kr, Velavan S, Mahesh R. In Vitro Antioxidant Activity and Total
Polyphenolic Content of Cyperus rotundus Rhizomes, E-Journal of Chemistry 2007;
4(3): p 440-449. 
46.  Gupta  MB,  Palit  TK,  Singh  N,  Bhargava KP.  Pharmacological  studies  to
isolate the active constituents from  Cyperus rotundus possessing anti-inflammatory,
anti-pyretic and analgesic activities. Indian Journal of Medical Research 1971; 59:
76–82.
47. Uddin  SJ,  Mondal  K,  Shilpi  JA,  Rahnan  MT.  Antidiarrhoeal  activity  of
Cyperus rotundus. Fitoterapia 2006; 77 (2): 134–136. 
48. Puratchikody A, Devi Nithya C, Nagalakshmi G. Wound healing activity of
cyperus rotundus linn. Indian journal of pharmaceutical sciences 2006; 68: 97-101. 
49. KemprajVivek,  Bhat  Sumangala  K.  Ovicidal  and  larvicidal  activities  of
Cyperus  giganteus  Vahl  and  Cyperus  rotundus Linn.  essential  oils  against  Aedes
albopictus (Skuse), Natural Product Radiance 2008; 7(5): 416-419. 
. Page 96
     
50. Kilani Soumaya, Ben Ammara Ribai, Bouhle Ines.  Investigation of extracts
from  (Tunisian)  Cyperus  rotundus as  antimutagens  and  radical  scavengers.
Environmental Toxicology and Pharmacology 2005; 20: 478–484. 
51. Komai KV.Chemical properties and behaviour of polyphenolic substances in
Cyperus rotundus. Zasso kenkya, 1975;20;66-71.
52. OECD guidelines for the testing of chemicals (Acute oral toxicity – up and
down  procedure).  Adopted  23rd  march  2006.  [cited  2008  Jun  20];  Available
from:URL:www.oecd.org.
53. C.K.  .Kokate,  A.P.Porohith  and  S.B.  Gokhale  (2007).  Text  Book  of
Pharmacognosy. 42 ndEdition, Pune : NiraliPrakashan, 2007, 108-109. 
54. A.S.Morani, S.L.Bodhankar. Neuroprotective Effect of Early Treatment with
Pioglitasone  and  Vitamin  E  Acetate  in  Alloxan  Induced  Diabetes  in  Rats.
Pharmacologyonline (2007) 3: 308-322
55. Kannan SA, Saade NE, Haddad JJ, Abdelnoor AM, Atweh SF and Jabbur SJ.
Endotoxin induced local inflammation and hyperalgesia in rats mince, a new model
for inflammatory pain. Pain. 1996; 66: 373-379.
56. Ramabadran K, Bansinath M, Turndorf H and Puig MM. The hyperalgesic
effect  of  naloxone  is  attenuated  in  streptozotocin  induced  diabetic  mice.
Psychopharmacology. 1989; 97: 169-174.
57. Kumar  KKS  and  Rajkapoor  B.  Study  on  phytochemical  profile  and  anti-
epileptic activity of Oxalis corniculata l. Int. J. Biol. Pharm. Res. 2010; 1: 34-37.
58. Allston,  C.A.,  Non  protein  nitrogenous  compounds  and  renal  function.
Clinical Chemistry: Concepts and Application, Anderson, S.C., Cockayne, S. (W.B.
Saunders eds. Philadel-phia USA), (1993), 369.
59. Thomas  L.  Clinical  Laboratory  Diagnostics.  1  ed.  Frankfurt:  TH-Books
Verlagsgesellschaft; 1998.p.208-14.
60. Newman DJ, Price CP. Renal  function and nitrogen metabolites.  In:  Burtis
CA, Ashwood  th ER, editors. Tietz fundamentals of Clinical Chemistry. 5 ed.
61. Henderson,  A.R.,  Moss,  D.W.,  Enzymes,  Tietz  Fundamentals  of  Clinical
Chemistry, 5 Ed., Burtis, C.A. & Ashwood, E.R. (W.B. Saunders eds. Philadelphia
USA), 2001, 352.
62. Johnson AM, Rohlfs EM, Silverman LM. Proteins. In: Burtis CA, Ashwood
ER. Editors Tietz textbook of clinical chemistry. 3rd ed. Philadelphia : W.B. Saunders
Company; 1999. p. 477-540.
. Page 97
     
63. Kelly,  C.  Understanding  the  fasting  blood  plasma  glucose  test,
http://www.about.fbpgt.com.2008. Retrieved online on 5th November 2010.
64. Jelodar, G., Mohsen, M., Shahram, S., 2003. Effect of Walnut leaf, coriander
and pomegranate on blood glucose and histopathology of pancreas of alloxan induced
diabetic  rats.  African  Journal  of  Traditional,  Complementary  and  Alternative
Medicines 3, 299–305.
65. Edem, D.O., 2009. Hypoglycemic effects of ethanolic extract of Aligator pear
seed (Persea Americana Mill)  in rats. European Journal  of Scientific Research 33,
669–678.
66. Lenzenand Panten,  .  Hypoglycemic  effects  of  ethanolic  extract  of  Aligator
pear seed (Persea Americana Mill) in rats. European Journal of Scientific Research
33, 669–678.
67. Funom,  T.M.,  2010.  Etiology  and  pathophysiology  of  diabetes  mellitus.,
www.ezinearticles.com.
68. Brownlee  M,  Biochemistry  and  molecular  cell  biology  of  diabetic
complications,  NATURE (414) 13 Dec 2001
69. Anjaneyulu  M,  Chopra  K,  Quercetin  attenuated  thermal  hyperalgesia  and  cold
allodynia in STZ-induced diabetic rats, Indian Journal of Experimental Biology; 42,
Aug 2004; 766-9.
70. Brownlee  M,  Biochemistry and  molecular  cell  biology  of  diabetic  complications,
NATURE (414) 13 Dec 2001.
71. Anjaneyulu  M,  Chopra  K,  Quercetin  attenuated  thermal  hyperalgesia  and  cold
allodynia in STZ-induced diabetic rats, Indian Journal of Experimental Biology;42,
Aug 2004; 766-9.
72. Szkudelski T, The mechanism of alloxan and streptozotocin action in B cells of the rat
pancreas, Physiol. Res. 50 (2001): 536-46.
73. M. M. Engelgau, K. M. V. Narayan, J. B. Saaddine, and F. Vinicor, "Addressing the
burden of diabetes in the 21st century: Better care and primary prevention," J. Am.
Soc. Nephrol., vol. 14, S88-S91, 2003. 
74. Bonnefont-Rousselot D, The role of antioxidant micronutrients in the prevention od
diabetic complications, Treat Endocrinol. 2004; 3(1): 41-52.
75. Aydemir O, Celebi S, Yilmaz T, Yekelar H and Kukenar AS, Protective effects of
Vitamin E forms (Alpha, gamma and d-alpha tocopherol Polyethylene Glycol 1000
. Page 98
     
Succinate)  on  retinal  edema during  ischemia/reperfusion  injury in  the  guinea  pig
retina, Int Ophthalmol, 2004 Oct; 25(5-6): 283-289.
76. Anjaneyulu  M,  Chopra  K,  Quercetin  attenuated  thermal  hyperalgesia  and  cold
allodynia in STZ-induced diabetic rats, Indian Journal of Experimental Biology;42,
Aug 2004; 766-9.
                              
. Page 99
     
PLANT
AUTHENTIFICATION
CERTIFICATE
. Page 100
     
ERRATA
. Page 101
     
  CPCSEA Approval
           Certificate
. Page 102
     
. Page 103
